WO2005051390A1 - E-fluoro-4-(pyridin-2-yl)-piperidine-1-carboxamide derivatives and related compounds which modulate the function of the vanilloid-1 receptor (vr1) for the treatment of pain - Google Patents

E-fluoro-4-(pyridin-2-yl)-piperidine-1-carboxamide derivatives and related compounds which modulate the function of the vanilloid-1 receptor (vr1) for the treatment of pain Download PDF

Info

Publication number
WO2005051390A1
WO2005051390A1 PCT/GB2004/004538 GB2004004538W WO2005051390A1 WO 2005051390 A1 WO2005051390 A1 WO 2005051390A1 GB 2004004538 W GB2004004538 W GB 2004004538W WO 2005051390 A1 WO2005051390 A1 WO 2005051390A1
Authority
WO
WIPO (PCT)
Prior art keywords
fluoro
piperidine
carboxamide
methylpyridin
trifluoromethylphenyl
Prior art date
Application number
PCT/GB2004/004538
Other languages
French (fr)
Inventor
Tracy Bayliss
Rebecca Elizabeth Brown
Frank Burkamp
A. Brian Jones
Joseph George Neduvelil
Original Assignee
Merck Sharp & Dohme Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme Limited filed Critical Merck Sharp & Dohme Limited
Priority to EP04769034A priority Critical patent/EP1682141A1/en
Priority to AU2004292382A priority patent/AU2004292382A1/en
Priority to US10/577,585 priority patent/US20070135423A1/en
Priority to JP2006537408A priority patent/JP2007509915A/en
Publication of WO2005051390A1 publication Critical patent/WO2005051390A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Definitions

  • the present invention is concerned with 4-substituted-4-pyridinyl-N-[4- 5 substitutedphenyl]piperidine-l-carboxamides and analogues and derivatives thereof as well as pharmaceutically acceptable salts and prodrugs thereof, which are useful as therapeutic compounds, particularly in the treatment of pain and other conditions ameliorated by the modulation of the function of the vanilloid-1 receptor (VRl).
  • VRl vanilloid-1 receptor
  • the pharmacologically active ingredient of chilli peppers has been recognised for some time to be the phenolic amide capsaicin.
  • the application of capsaicin to mucous membranes or when injected intradermally, causes intense burning-like pain in humans.
  • the beneficial effects of topical administration of capsaicin as an analgesic is also well established.
  • VRl receptor The receptor for capsaicin, termed the vanilloid VRl receptor, was cloned by Caterina and colleagues at UCSF in 1997 (Nature, 398:816, 1997).
  • VRl receptors are cation channels that are found on sensory nerves that innervate the 20 skin, viscera, peripheral tissues and spinal cord. Activation of VRl elicits action potentials in sensory fibres that ultimately generate the sensation of pain.
  • the VRl receptor is activated not only by capsaicin but also by acidic pH and by noxious heat stimuli.
  • VRl antagonist is capsazepine (Walpole et al, J. Med. Chew., 37:1942, 1994) - VRl IC50 of 420nM.
  • a novel series of sub- micromolar antagonists has also been reported recently (Lee et al, Bioorg. Med. Chew., 9:1713, 2001), but these reports provide no evidence for in 30 vivo efficacy.
  • a much higher affinity antagonist has been derived from the 'ultra- potent' agonist resiniferatoxin. Iodo-resiniferatoxin (Wahl et al., Mol.
  • a 1 is phenyl, a six-membered aromatic heterocycle containing one, two or three nitrogen atoms, or a five-membered aromatic heterocycle containing up to four heteroatoms chosen from O, N and S, at most one heteroatom being O or S;
  • a 1 is unsubstituted or substituted by one, two or three substituents independently chosen from halogen, Ci- ⁇ alkyl, C 2 -6alkenyl, C 2 -6alkynyl, haloCi-ealkyl, Ci- ⁇ alkoxy, haloCi- ⁇ alkoxy, hydroxy, cyano, nitro and amino!
  • a 2 is phenyl, a six-membered aromatic heterocycle containing one, two or three nitrogen atoms, or a five-membered aromatic heterocycle containing up to four heteroatoms chosen from O, N and S, at most one heteroatom being O or S.
  • a 2 is unsubstituted or substituted by one, two or three groups independently chosen from halogen, cyano, nitro, amino, Ci ealkylamino, di(C ⁇ -6alkyl)amino, Ci- ⁇ alkyl C 2 -6alkenyl, C2-ealkynyl, haloCi-ealkyl, hydroxy, Ci- ⁇ alkoxy, haloCi-ealkyl, thiol, SF ⁇ , phenylCi- ⁇ alkyl and phenyl; L is a bond or Ci-ealkylene; R 1 and R 2 independently chosen from hydrogen and Ci-ealkyl; or R 1 and R 2 may, together, form a methylene or ethylene bridge; W is halogen, Ci- ⁇ alkyl, haloCi- ⁇ alkyl, Ci- ⁇ alkoxy or haloCi- ⁇ alkoxy; X is O, S or NR 3 where R 3 is hydrogen, hydroxy, Ci- ⁇
  • a 1 is preferably phenyl or a nitrogen containing heterocycle which is unsubstituted or substituted with one or two groups independently chosen from halogen, hydroxy, cyano, nitro, amino, C ⁇ - 4 alkyl, haloC ⁇ - 4 alkyl, Ci- ⁇ alkoxy and haloC ⁇ - 4 alkoxy. More particularly A 1 is phenyl, pyridinyl, pyrimidinyl or imidazolyl. Preferred substituents are halogen, C ⁇ - 4 alkyl, C ⁇ - 4 alkoxy and haloC ⁇ -4alkyl, such as fluorine, chlorine, methyl, methoxy and trifluoromethyl.
  • a 1 include 3-methylpyrid-2-yl, pyrid-2-yl, 1- methylimidazol-2-yl, 3-chloropyrid-2-yl, 3-fluoropyrid-2-yl, 3-methoxypyrid-2-yl, phenyl, pyrimidin-2-yl and 3-trifluoromethylpyrid-2-yl.
  • a 2 is preferably a six-membered aromatic or heteroaromatic ring.
  • a 2 is preferably monosubstituted, particularly para to the point of attachment to Y.
  • the substituent is preferably haloCi- ⁇ alkyl, Ci- ⁇ alkyl, SFs, phenyl, phenylCi-ealkyl, haloCi-ealkoxy, cyano or di(C ⁇ -6alkyl)amino. More preferably the substituent is haloC ⁇ -4alkyl, C ⁇ -4alkyl, SFs, phenyl, phenylC ⁇ - 2 alkyl, haloC ⁇ -4alkoxy, cyano or di(C ⁇ -4alkyl)amino.
  • substituents include trifluoromethyl, isopropyl, 1,2,2,2-tetrafluoro-l-trifluoromethylethyl, tert-butyl, SFs, n-butyl, benzyl, phenyl, 2,2,2-trifluoroethyl, trifluoromethoxy, cyano and dimethylamino.
  • a 2 is preferably phenyl or pyridyl, particularly phenyl.
  • Particular embodiments of A 2 include 4-trifl.uoromethylphenyl, 4- isopropylphenyl, 4-(l,2,2,2-tetrafluoro- l-trifluoromethylethyl)phenyl, 4- benzylphenyl, 4-(pentafluoro- ⁇ e -sulfonyl)phenyl, biphenyl, 3- trifluoromethylpyrid-6-yl, 4-(2,2,2-trifluoroethyl)phenyl, 4- trifluoromethoxyphenyl, 4-cyanophenyl and 4-dimethylaminophenyl.
  • One embodiment is 4-trifluoromethylphenyl.
  • L is preferably a bond or C ⁇ -3alkylene, such as ethylene. Most preferably L is a bond.
  • R 1 and R 2 are preferably independently hydrogen, C ⁇ - 2 alkyl or together form a methylene or ethylene bridge. More preferably they are hydrogen, methyl or an ethylene bridge. In one embodiment both are hydrogen.
  • W is preferably halogen, C ⁇ -4alkyl, haloC ⁇ -4alkyl, C ⁇ - 4 alkoxy or haloC ⁇ - 4 alkoxy. More preferably W is halogen, C ⁇ -2alkoxy or haloC ⁇ -2alkyl. Particular embodiments of W include fluorine, methoxy and fluoromethyl.
  • X is preferably O, S, or NR 3 where R 3 is hydrogen, hydroxy, Ci- ⁇ alkyl,
  • alkyl or "alkoxy" as a group or part of a group means that the group is straight or branched.
  • suitable alkyl groups include methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl and t-butyl.
  • suitable alkoxy groups include methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, s-butoxy and t-butoxy.
  • Alkylthio shall be construed in an analogous manner.
  • haloCi- ⁇ alkyl and “haloCi- ⁇ alkoxy” means a
  • Ci- ⁇ alkyl or Ci- ⁇ alkoxy group in which one or more (in particular, 1 to 3) hydrogen atoms have been replaced by halogen atoms, especially fluorine or chlorine atoms.
  • fluoroCi- ⁇ alkyl and fluoroCi- ⁇ alkoxy groups in particular, fluoroC ⁇ -3alkyl and fluoroC ⁇ -3alkoxy groups, for example, CF3, CH2CH2F,
  • alkenyl and alkynyl as a group or part of a group means that the group is straight or branched.
  • suitable alkenyl groups include vinyl and allyl.
  • a suitable alkynyl group is acetylene or propargyl.
  • halogen means fluorine, chlorine, bromine and iodine. The most preferred halogens are fluorine and chlorine, especially fluorine.
  • 6-mer ⁇ bered heterocycles are pyridine, pyrimidine, pyrazine, pyridazine and triazine.
  • 5-membered heterocycles are thiophene, furan, pyrrole, imidazole, pyrazole, oxazole, isoxazole, thiazole, isothiazole, 1,2,3-triazole, 1,2,4- triazole, oxadiazole, thiadiazole and tetrazole.
  • the compounds of formula I may be prepared in the form of a pharmaceutically acceptable salt, especially an acid addition salt.
  • the salts of the compounds of formula I will be non-toxic pharmaceutically acceptable salts.
  • Suitable pharmaceutically acceptable salts of the compounds of this invention include acid addition salts which may, for example, be formed by mixing a solution of the compound according to the invention with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, fumaric acid, p-toluenesulphonic acid, maleic acid, succinic acid, acetic acid, citric acid, tartaric acid, carbonic acid, phosphoric acid or sulphuric acid.
  • a further salt is the acid addition salt with benzenesulfonic acid.
  • Preferred pharmaceutically acceptable salts of the compounds of the present invention are the besylate salts.
  • Salts of amine groups may also comprise quaternary ammonium salts in which the amino nitrogen atom carries a suitable organic group such as an alkyl, alkenyl, alkynyl or aralkyl moiety.
  • suitable pharmaceutically acceptable salts thereof may include metal salts such as alkali metal salts, e.g. sodium or potassium salts; and alkaline earth metal salts, e.g. calcium or magnesium salts.
  • the salts may be formed by conventional means, such as by reacting the free base form of the compound of formula I with one or more equivalents of the appropriate acid in a solvent or medium in which the salt is insoluble, or in a solvent such as water which is removed in vacuo or by freeze drying or by exchanging the anions of an existing salt for another anion on a suitable ion exchange resin.
  • the present invention also includes within its scope N-oxides of the compounds of formula I above. In general, such N-oxides may be formed on any available nitrogen atom.
  • the N-oxides may be formed by conventional means, such as reacting the compound of formula I with oxone in the presence of wet alumina.
  • the present invention includes within its scope prodrugs of the compounds of formula I above.
  • prodrugs will be functional derivatives of the compounds of formula I which are readily convertible in vivo into the required compound of formula I.
  • Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in "Design of Prodrugs", ed. H. Bundgaard, Elsevier, 1985.
  • a prodrug may be a pharmacologically inactive derivative of a biologically active substance (the "parent drug” or "parent molecule”) that requires transformation within the body in order to release the active drug, and that has improved delivery properties over the parent drug molecule.
  • the transformation in vivo may be, for example, as the result of some metabolic process, such as chemical or enzymatic hydrolysis of a carboxylic, phosphoric or sulphate ester, or reduction or oxidation of a susceptible functionality.
  • the present invention includes within its scope solvates of the compounds of formula I and salts thereof, for example, hydrates.
  • the compounds according to the invention may have one or more asymmetric centres, and may accordingly exist both as enantiomers and as diastereoisomers. It is to be understood that all such isomers and mixtures thereof are encompassed within the scope of the present invention.
  • the compounds of formula I may also exist in tautomeric forms and the invention includes within its scope both mixtures and separate individual tautomers.
  • compositions comprising one or more compounds of formula I in association with a pharmaceutically acceptable carrier or excipient.
  • compositions according to the invention are in unit dosage forms such as tablets, pills, capsules, powders, granules, sterile parenteral solutions or suspensions, metered aerosol or liquid sprays, drops, ampoules, auto- injector devices, suppositories, creams or gels; for oral, parenteral, intrathecal, intranasal, sublingual, rectal or topical administration, or for administration by inhalation or insufflation.
  • compositions such as tablets, pills, capsules or wafers are particularly preferred.
  • a pharmaceutical carrier e.g. conventional tabletting ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate or gums, and other pharmaceutical diluents, e.g. water, to form a solid pre-formulation composition containing a homogeneous mixture of a compound of the present invention, or a pharmaceutically acceptable salt thereof.
  • pre-formulation compositions as homogeneous, it is meant that the active ingredient is dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules.
  • This solid pre-formulation composition is then subdivided into unit dosage forms of the type described above containing from 0.1 to about 500 mg of the active ingredient of the present invention.
  • Favoured unit dosage forms contain from 1 to 500 mg, for example 1, 5, 10, 25, 50, 100, 300 or 500 mg, of the active ingredient.
  • the tablets or pills of the novel composition can be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action.
  • the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former.
  • the two components can be separated by an enteric layer that serves to resist disintegration in the stomach and permits the inner component to pass intact into the duodenum or to be delayed in release.
  • enteric layers or coatings such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol and cellulose acetate.
  • liquid forms in which the novel compositions of the present invention may be incorporated for administration orally or by injection include aqueous solutions, suitably flavoured syrups, aqueous or oil suspensions, and flavoured emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil or peanut oil, as well as elixirs and similar pharmaceutical vehicles.
  • Suitable dispersing or suspending agents for aqueous suspensions include synthetic and natural gums such as tragacanth, acacia, alginate, dextran, sodium carboxymethylcellulose, methylcellulose, polyvinyl-pyrrolidone or gelatin.
  • a suitable dosage level is about 1.0 mg to 15 g per day, preferably about 5.0 mg to 1 g per day, more preferably about 5 mg to 500 mg per day, especially 10 mg to 100 mg per day.
  • the compounds may be administered on a regimen of 1 to 4 times per day. It will be appreciated that the amount of a compound of formula I required for use in any treatment will vary not only with the particular compounds or composition selected but also with the route of administration, the nature of the condition being treated, and the age and condition of the patient, and will ultimately be at the discretion of the attendant physician.
  • the invention further provides a compound of formula I as defined above, or a pharmaceutically acceptable salt thereof, for use in treatment of the human or animal body.
  • said treatment is for a condition which is susceptible to treatment by modulation (preferably antagonism) of VRl receptors.
  • the compounds of the present invention will be of use in the prevention or treatment of diseases and conditions in which pain and/or inflammation predominates, including chronic and acute pain conditions.
  • diseases and conditions include rheumatoid arthritis! osteoarthritis; post-surgical pain; muscukrskeletal pain, particularly after trauma; spinal pain; myofascial pain syndromes! headache, including migraine, acute or chronic tension headache, cluster headache, temporomandibular pain, and maxillary sinus pain; ear pain!
  • episiotomy pain burns, and especially primary hyperalgesia associated therewith; deep and visceral pain, such as heart pain, muscle pain, eye pain, orofacial pain, for example, odontalgia, abdominal pain, gynaecological pain, for example, dysmenorrhoea, pain associated with cystitis and labour pain, chronic pelvic pain, chronic prostatitis and endometriosis; pain associated with nerve and root damage, such as pain associated with peripheral nerve disorders, for example, nerve entrapment and brachial plexus avulsions, amputation, peripheral neuropathies, tic douloureux, atypical facial pain, nerve root damage, and arachnoiditis; itching conditions including pruritis, itch due to hemodialysis, and contact dermatitis; pain (as well as broncho-constriction and inflammation) due to exposure (e.g.
  • neuropathic pain conditions such as diabetic neuropathy, chemotherapy-induced neuropathy and post-herpetic neuralgia; "non-painful" neuropathies; complex regional pain syndromes; pain associated with carcinoma, often referred to as cancer pain; central nervous system pain, such as pain due to spinal cord or brain stem damage, low back pain, sciatica and ankylosing spondylitis; gout; scar pain!
  • irritable bowel syndrome inflammatory bowel disease; urinary incontinence including bladder detrusor hyper-reflexia and bladder hypersensitivity; respiratory diseases including chronic obstructive pulmonary disease (COPD), chronic bronchitis, cystic fibrosis, asthma and rhinitis, including allergic rhinitis such as seasonal and perennial rhinitis, and non-allergic rhinitis and cough; autoimmune diseases; and immunodeficiency disorders.
  • COPD chronic obstructive pulmonary disease
  • COPD chronic obstructive pulmonary disease
  • cystic fibrosis cystic fibrosis
  • asthma and rhinitis including allergic rhinitis such as seasonal and perennial rhinitis, and non-allergic rhinitis and cough
  • autoimmune diseases and immunodeficiency disorders.
  • the compounds of the present invention may also be used to treat depression. They may also be used to treat gastro-oesophageal reflux disease (GERD), particularly the pain associated with GERD.
  • the present invention provides a compound of formula I for use in the manufacture of a medicament for the treatment or prevention of physiological disorders that may be ameliorated by modulating VRl activity.
  • the present invention also provides a method for the treatment or prevention of physiological disorders that may be ameliorated by modulating VRl activity, which method comprises administration to a patient in need thereof of an effective amount of a compound of formula I or a composition comprising a compound of formula I.
  • the present invention provides a compound of formula I for use in the manufacture of a medicament for the treatment or prevention of a disease or condition in which pain and/or inflammation predominates.
  • the present invention also provides a method for the treatment or prevention of a disease or condition in which pain and/or inflammation predominates, which method comprises administration to a patient in need thereof of an effective amount of a compound of formula I or a composition comprising a compound of formula I.
  • the compound of formula I and the other pharmacologically active agent(s) may be administered to a patient simultaneously, sequentially or in combination.
  • a compound of the present invention may be used in conjunction with other analgesics, such as acetaminophen (paracetamol), aspirin and other NSAIDs, including selective cyclooxygenase-2 (COX-2) inhibitors, as well as opioid analgesics, especially morphine, NR2B antagonists, bradykinin antagonists, anti-migraine agents, anticonvulsants such as oxcarbazepine and carbamazepine, antidepressants (such as TCAs, SSRIs, SNRIs, substance P antagonists, etc.), spinal blocks, gabapentin, pregabalin and asthma treatments (such as &2 _ adrenergic receptor agonists or leukotriene D 4 antagonists (e.g.
  • Specific anti-inflammatory agents include diclofenac, ibuprofen, indomethacin, nabumetone, ketoprofen, naproxen, piroxicam and sulindac, etodolac, meloxicam, rofecoxib, celecoxib, etoricoxib, parecoxib, valdecoxib and tilicoxib.
  • Suitable opioid analgesics of use in conjunction with a compound of the present invention include morphine, codeine, dihydrocodeine, diacetylmorphine, hydrocodone, hydromorphone, levorphanol, oxymorphone, alfentanil, buprenorphine, butorphanol, fentanyl, sufentanyl, meperidine, methadone, nalbuphine, propoxyphene and pentazocine; or a pharmaceutically acceptable salt thereof.
  • Suitable anti-migraine agents of use in conjunction with a compound of the present invention include CGRP-antagonists, ergotamines or 5 ⁇ T ⁇ agonists, especially sumatriptan, naratriptan, zolmatriptan or rizatriptan. Therefore, in a further aspect of the present invention, there is provided a pharmaceutical composition comprising a compound of the present invention and an analgesic, together with at least one pharmaceutically acceptable carrier or excipient. In a further or alternative aspect of the present invention, there is provided a product comprising a compound of the present invention and an analgesic as a combined preparation for simultaneous, separate or sequential use in the treatment or prevention of a disease or condition in which pain and/or inflammation predominates.
  • the compounds of formula I in which Y is NH or NH(CH2) ⁇ -3 can be made by reacting a compound of formula II with a compound of formula III: (ID (III)
  • X 1 is O or S
  • P is H or a C ⁇ -6alkoxycarbonyl group such as tert- butoxycarbonyl and A 1 , A 2 , L, R 1 , R 2 and W are as defined above.
  • the reaction is generally carried out in a solvent such as dichloromethane in the presence of a base such as triethylamine at about room temperature for about one hour.
  • a base such as triethylamine
  • a 1 , R 1 , R 2 and P are as defined above and L 1 is a leaving group such as H or Br.
  • the compound of formula VI is first converted to its anion by reacting with a strong base such as N-butyl lithium in hexanes and then reacted with the compound of formula VII generally in a solvent such as THF between -78°C and room temperature for several hours.
  • the resulting group W can be converted into other groups W by standard methods known in the art.
  • a hydroxy group can be converted to a fluorine atom by reacting with diethylaminosulphur trifluoride in a solvent such as dichloromethane at a temperature between -78°C and room temperature for about two hours.
  • a hydroxy group can be converted to an alkoxy group by reacting first with a strong base such as sodium hydride in a solvent such as a mixture of tetrahydrofuran and dimethyl formamide for about two hours followed by addition of the appropriate alkyl iodide and leaving to react for about 3 days.
  • a strong base such as sodium hydride
  • a solvent such as a mixture of tetrahydrofuran and dimethyl formamide
  • a 1 and R are as defined above in the presence of a strong base such as sodium hydride in a solvent such as anhydrous dimethylformamide at about 60°C for about 5/4 hours.
  • the cyano group can be converted to an ester using hydrogen chloride gas in anhydrous methanol. This can be reduced to a hydroxymethyl group using a reagent such as lithium aluminium hydride in a solvent such as tetrahydrofuran at about -30°C for about one hour.
  • This group can be converted to a fluoromethyl group using a reagent such as diethylaminosulphur trifluoride in a solvent such as anhydrous ethyl acetate at between -78°C and room temperature for several hours.
  • Compounds of formula III in which X 1 is O can be made by reacting the corresponding amine with triphosgene followed by a base such as triethylamine in a solvent such as dichloromethane for about one hour.
  • Compounds of formula III in which X 1 is O can be made by reacting the corresponding carboxylic acid with an azide such as diphenyl phosphoryl azide in the presence of a base such as triethylamine at about 90°C for about 3 hours so that a Curtius rearrangement occurs.
  • Compounds of formula " VTI can be made by hydrogenating a compound of formula IX:
  • Example 3 2-(4-Fluoropiperidin-4-yl)-3-methylpyridine Description Example 2 (l.44g, 4.9mmol) in dichloromethane (20ml) was treated with trifluoroacetic acid (5ml) and stirred at room temperature for 3 hours. The reaction mixture was evaporated and purified using a strong cation exchange cartridge to give the desired product (710mg).
  • Example 1 Description Example 1 (557mg, 2mmol) in THF (5ml) was treated with sodium hydride (56mg, 95% dry, 2.2mmol) and stirred at room temperature for 20 minutes. Dimethylformamide (5ml) was added to aid solubility of the anion formed. Iodomethane (l31 ⁇ l) was added. After 2 hours and 4 hours, further iodomethane (50 ⁇ l) was added. The reaction was stirred for 72 hours. Water
  • Example 1 4-Fluoro-4-(3-methylpyridin-2-yl)-N-[4- trifluoromethylphenyl] piperidine- 1-carboxamide Trifluoroacetic acid (2ml) was added to a stirred solution of Description Example 2 ( ⁇ lOmg, 1.73mmol) in dichloromethane (8ml). After 1 hour, the reaction was complete and the solvent was removed by evaporation. The residue was dissolved in dichloromethane (lOml), treated with triethylamine (l.25ml) followed by 4- trifluoromethylphenyl isocyanate (324mg, 1.73mmol) and stirred at room temperature for 1 hour. The reaction mixture was evaporated and purified by column chromatography on silica using 20-33% ethyl acetate in isohexane to give the desired product (470mg).
  • Example 2 4-Fluoro-4(pyridin-2-yl)N-[4-trifluoromethylphenyl]piperidine-l- carboxamide Using Description Example 4 and the procedure shown in Example 1, the title compound was obtained.
  • Example 5 2-(4-Fluoro-l- ⁇ f4-trifluoromethylphenyl]acetyl ⁇ piperidin-4- vQpyridine Using Description Example 4, 4-trifluoromethylphenyl acetic acid and the procedure shown in Example 4, the title compound was obtained.
  • Example 6 2-(4-Fluoro-l- ⁇ 3-[4-trifluoromethylphenyllpropanoyl ⁇ piperidin-4- vOpyridine Using Description Example 4, 4-trifluoromethylhydrocinnamic acid and the procedure shown in Example 4, the title compound was obtained.
  • Example 7 4-Fluoro-4-(l-methyl-lH-imidazol-2-yl)-N-[4-trifluoromethylphenyll piperidine- l'carboxamide
  • the title compound was prepared in analogous fashion to Example 1 from Description Example 5.
  • MSp m/z for MH+ 371.
  • Example 9 4-Methoxy-4-pyridin-2-yl-N ' -[4-trifluoromethylbenzyl]piperidine-l- carboxamide The title compound was obtained using the procedure shown in Example 8 and employing Description Example 6 and [4-trifluoromethylbenzyl]isocyanate.
  • Example 10 4-Fluoro-N-(4-isopropylphenyl)-4-(3-methylpyridin-2-yl)piperidine- 1-carboxamide 4-isopropylphenylisocyanate (40.3mg, 0.25mmol) in dichloromethane (lml) was treated with Description Example 3 (48.5mg, 0.25mmol) in dichloromethane 5 (lml) and stirred overnight at room temperature. The compound was purified by column chromatography on silica using 20-40% ethyl acetate in isohexane the eluant to give the desired compound (75mg).
  • Example 11 4-Fluoro-4-(3-methylpyridin-2-yl)-7y r - ⁇ 4-[l.2.2.2-tetrafluoro-l- trifluoromethylethyll phenyllpiperidine- 1 -carboxamide5
  • Example 3 (97mg, O. ⁇ mmol) in dichloromethane (lml) was added and the reaction mixture was stirred at room temperature overnight. Water (2ml) was added and the organics0 were separated using a phase separation cartridge. The compound was purified using a strong cation exchange cartridge followed by column chromatography on silica using 20% ethyl acetate in hexane as the eluant to give the desired compound (l ⁇ mg).
  • Example 12 N-(4- Tert-butylphenyl)-4-fluoro-4-(3-methylpyridin-2-yl)piperidine- 1 -carboxamide0
  • the title compound was obtained using the procedure shown in Example 10 using 4-tert-butylphenyl isocyanate and Description Example 3.
  • Example 14 A ⁇ -(4-Butylphenyl)-4-fluoro-4-(3-methylpyridin-2-yl)piperidine-l- carboxamide The title compound was obtained using the procedure shown in Example 10 using 4-n-butylphenyl isocyanate and Description Example 3.
  • Example 17 4-Fluoro-4-(3-methylpyridin-2-yl)-N-[5-trifluoromethylpyridin-2- yl]piperidine-l-carboxamide 5-Trifluoromethylpyridine-2-carboxyHc acid (I91mg, lmmol), diphenyl phosphoryl azide (275mg, lmmol) and triethylamine(202mg, 2mmol) was heated at 90 °C for 3 hours. Description Example 3 (l95mg, lmmol) was added to the reaction mixture and stirred at room temperature for 72 hours. The reaction mixture was evaporated, partitioned between water (2ml) and dichloromethane (5ml) in a phase separation cartridge. The aqueous phase was washed with more dichloromethane and the combined organics were evaporated. The compound was purified by mass-triggered HPLC to give the desired compound (27mg).
  • Example 18 4- (3 - Chlorop yridin- 2 - yl) -4-fluoro- N- [4-trifluoromethylphenyll piperidine- 1 -carboxamide l,4-diazabicyclo[2.2.2]octane (3.08g,27.5mmol) in diethyl ether (llOml) was treated with n-butyl lithium in hexanes (17.2ml, 1.6M, 25mmol) at -40 °C keeping the temperature in the range -40 °C to -30 °C, and stirred in this temperature range for 1 hour.
  • Example 19 4-Fluoro-4-(3-fluoropyridin-2-yl)-A/-f4-trifluoromethylphenyl1 piperidine- l'carboxamide
  • the title compound was obtained using the chemistry described in Example 18, using 3-fluoropyridine as the starting material.
  • Example 20 4-Fluoro-4-(3-methoxypyridin-2-yl)-N-[4-trifluoromethylphenyll piperidine- 1 -carboxamide
  • the title compound was prepared from 2-bromo-3-methoxypyridine using the chemistry described for Description Example 1 and Example 1.
  • Example 23 4-Fluoro-4-(3-methylpyridin-2-yl)-N-(l-phenylpiperidin-4-yl)-N-[4- trifluoromethylphenyl] piperidine- 1 -carboximidamide
  • Example 21 (397mg, lmmol), l-phenylpiperidin-4-ylamine (l76mg, lmmol) and silver acetate (l67mg, lmmol) in acetonitrile (20ml) were heated at reflux overnight.
  • reaction mixture was evaporated, purified by column chromatography on silica using 2-10% methanol in dichloromethane as the eluant, followed by mass triggered HPLC purification using an acid based eluant.
  • the free base was liberated using a strong cation exchange cartridge to give the desired compound (40mg).
  • Step 2 Methyl 4-hydroxy-2-methyl-4-(3-methylpyridin-2-yl)piperidine-l- carboxylate was synthesized in the same manner as Description Example 1 using the product of Step 1 and 2-bromo-3-methylpyridine.
  • Step 3 47% hydrogen bromide in acetic acid (3ml, excess) was added dropwise to a stirred solution of the product of Step 2 (361mg, 1.4mmoles) in acetic acid (lml) and stirred at room temperature for 48 hours. The reaction was concentrated in vacuo to give a pale brown solid.
  • Step 4 To a suspension of the product of Step 3 (221mg, 0.56mmol) in dichloroethane (lOml) at -78°C diethylaminosulphur trifluoride (l44 ⁇ l, 1.18mmol) was added dropwise. Workup was analogous to Description Example 2, to give crude product which was purified via column chromatography on silica using 10-20% ethyl acetate in isohexane to give the desired product (8mg, 4%).
  • Example 26 4-(Fluoromethyl)-4-pyridin-2-yl-N-[4-trifluoromethylphenyl] piperidine- 1-carboxamide Step 1: Sodium hydride (60% in mineral oil, 2.04g, ⁇ lmmol) was added portion wise over 8 minutes to a stirring solution of 2-pyridineacetonitrile (l.8ml,
  • Step 3 Lithium aluminium hydride (lM in tetrahydrofuran, lml, lmmol) was added to a stirred solution of the product of Step 2 (320mg, lmmol) in anhydrous THF (3ml) at -30°C and stirred at this temperature for 1 hour. Water (2ml) was added then extracted into ethyl acetate (2 x 5ml) organic layers combined, dried over anhydrous MgSO4, filtered, filtrate evaporated in vacuo to give (l-benzyl-4- pyridin-2-ylpiperidin-4-yl)methanol as an orange oil which solidified on standing (263mg, 93%).
  • Step 4 A slurry of 10% palladium on carbon (84mg) was added to a solution of the product of Step 3 (l24mg, 0.44mmol) in ethanol (lOml). This was hydrogenated at room temperature under atmospheric pressure for 72 hours. The catalyst was filtered, washed with ethanol, and the filtrate concentrated in vacuo. The resulting amine (85mg, 0.44mmol) was dissolved in dichloromethane (lOml), to the stirring solution drtert-butyldicarbonate (95mg, 0.44mmol) added and stirred at room temperature for 2 hours.
  • Step 5 Diethylaminosulphur trifluoride (76 ⁇ l, 0.62mmol) was added to a stirring solution of the product of Step 4 (I20mg, 0.41mmol) in anhydrous ethyl acetate (3ml) at — 78°C. The reaction was allowed to warm to RT overnight. The solution was evaporated and to the resulting oil tetrabutylammonium fluoride (1M solution in tetrahydrofuran, 820 ⁇ l 0.82mmol) added and refluxed for 2 hours. The reaction was cooled to RT water (3ml) added and the aqueous layer was • extracted with ethyl acetate (3 x 5ml).
  • Step 2a The major isomer of the product of Step 1 was treated according to the procedure in Example 1 to give the title compound (Example 27).
  • MSp m/z for MH+ 394.
  • Step 2b The minor isomer of the product of Step 1 was treated according to the procedure in Example 1 to give the title compound (Example 28).
  • MSp m/z for MH+ 394.
  • Step !' ⁇ 4-Hydroxy-4-pyrimidin-2-ylpiperidine-l-carboxylic acid fort-butyl ester was prepared according to WO-A-9903847 and then treated according to the procedure in Description Example 2 to give 4-fluoro-4-pyrimidin-2-ylpiperidine-l- carboxylic acid fert-butyl ester.
  • Step 2 The product of Step 1 was treated according to the procedure in Example 1 to give the title compound.
  • MSp m/z for MH+ 369.
  • Example 30 4-Fluoro-4-(3-phenylpropyl)-N-[4-trifluoromethylphenyllpiperidine- 1 -carboxamide
  • the title compound was prepared using a procedure analogous to that in Example 7 using 4-fluoro-4-(3-phenylpropyl)piperidine hydrochloride as the amine.
  • Example 31 2- [4-Fluoro-4-(3-methylpyridin-2-yl)piperidin- 1-yl] -6- trifluoromethyl- lH-benzimidazole Description Example 3 (87.2mg, 0.46mmol) was treated with ethanol (lml) and 2- chloro-5-(trifluoromethyl)-lH-benzimidazole (lOOmg, 0.46mmol) (WO-A-021471) and heated in a pressurized microwave vessel at 160°C for 10 minutes.
  • Example 32 2-(4-Fluoi -4-pyridin-2-ylpiperidin-l-yl)-6-(trifluoromethyl)-lJ_ " - benzimidazole
  • the title compound was prepared using a procedure analogous to that in 5 Example 31 from Description Example 4.
  • MSp m/z for MH+ 365.
  • Examples 34 to 39 were made using the procedure shown in Example 10 using 30 Description Example 3 and 4-tolyl isocyanate, 4-ethylphenyl isocyanate, 4- chlorophenyl isocyanate, 4-trifluoromethoxy isocyanate, 4-cyanophenyl isocyanate and 4-dimethylammophenyl isocyanate respectively.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Compounds of formula (I): wherein: A1 is phenyl, a six-membered aromatic heterocycle containing one, two or three nitrogen atoms, or a five-membered aromatic heterocycle containing up to four heteroatoms chosen from O, N and S, at most one heteroatom being O or S; A2 is phenyl, a six-membered aromatic heterocycle containing one, two or three nitrogen atoms, or a five-membered aromatic heterocycle containing up to four heteroatoms chosen from 0, N and S, at most one heteroatom being O or S; L is a bond or C1-6alkylene; R1 and R2 independently chosen from hydrogen and C1-6alkyl or Rl and R2 may, together, form a methylene or ethylene bridge; W is halogen, C1-6alkyl, haloC1-6alkyl, C1-6alkoxy or haloC1-6alkoxy; X is O, S or NR3 or X, together with the atom to which it is attached, and Y, form an unsaturated five-membered ring together with A2; Y is a bond, C1-4alkylene, NH or NH(CH2)1-3; or a pharmaceutically acceptable salt thereof; other substituents are defined in claim 1; which are useful as therapeutic compounds, particularly in the treatment of pain and other conditions ameliorated by the modulation of the function of the vanilloid-1 receptor (VR1).

Description

4-FLUORO-4- ( PYRIDIN-2-YL) -PIPERIDINE-l-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS WHICH MODULATE THE FUNCTION OF THE VANILLOID-1 RECEPTOR (VRl ) FOR THE TREATMENT OF PAIN
The present invention is concerned with 4-substituted-4-pyridinyl-N-[4- 5 substitutedphenyl]piperidine-l-carboxamides and analogues and derivatives thereof as well as pharmaceutically acceptable salts and prodrugs thereof, which are useful as therapeutic compounds, particularly in the treatment of pain and other conditions ameliorated by the modulation of the function of the vanilloid-1 receptor (VRl). 10 The pharmacologically active ingredient of chilli peppers has been recognised for some time to be the phenolic amide capsaicin. The application of capsaicin to mucous membranes or when injected intradermally, causes intense burning-like pain in humans. The beneficial effects of topical administration of capsaicin as an analgesic is also well established. However, understanding of the 15 underlying molecular pharmacology mediating these responses to capsaicin has been a more recent development. The receptor for capsaicin, termed the vanilloid VRl receptor, was cloned by Caterina and colleagues at UCSF in 1997 (Nature, 398:816, 1997). VRl receptors are cation channels that are found on sensory nerves that innervate the 20 skin, viscera, peripheral tissues and spinal cord. Activation of VRl elicits action potentials in sensory fibres that ultimately generate the sensation of pain. Importantly the VRl receptor is activated not only by capsaicin but also by acidic pH and by noxious heat stimuli. It is also sensitized by a number of inflammatory mediators and thus appears to be a polymodal integrator of painful 25 stimuli. The prototypical VRl antagonist is capsazepine (Walpole et al, J. Med. Chew., 37:1942, 1994) - VRl IC50 of 420nM. A novel series of sub- micromolar antagonists has also been reported recently (Lee et al, Bioorg. Med. Chew., 9:1713, 2001), but these reports provide no evidence for in 30 vivo efficacy. A much higher affinity antagonist has been derived from the 'ultra- potent' agonist resiniferatoxin. Iodo-resiniferatoxin (Wahl et al., Mol. Pharwacol., 59:9, 2001) is a nanomolar antagonist of VRl but does not possess properties suitable for an oral pharmaceutical. This last is also true of the micro molar pe toid antagonists described by Garcia-Martinez (Proc. Natl. Acad. Sex., USA, 99:2374, 2002). WO-A-0208221 (Neurogen Corporation et al) discloses structurally related VRl antagonists based around a piperazine core. We herein describe another novel series of VRl modulators. These comprise predominantly VRl antagonists but encompass VRl partial antagonists and VRl partial agonists. Such compounds have been shown to be efficacious in animal models of pain. The present invention provides compounds of formula I:
Figure imgf000003_0001
(I)
wherein: A1 is phenyl, a six-membered aromatic heterocycle containing one, two or three nitrogen atoms, or a five-membered aromatic heterocycle containing up to four heteroatoms chosen from O, N and S, at most one heteroatom being O or S; A1 is unsubstituted or substituted by one, two or three substituents independently chosen from halogen, Ci-βalkyl, C2-6alkenyl, C2-6alkynyl, haloCi-ealkyl, Ci-βalkoxy, haloCi-βalkoxy, hydroxy, cyano, nitro and amino! A2 is phenyl, a six-membered aromatic heterocycle containing one, two or three nitrogen atoms, or a five-membered aromatic heterocycle containing up to four heteroatoms chosen from O, N and S, at most one heteroatom being O or S. A2 is unsubstituted or substituted by one, two or three groups independently chosen from halogen, cyano, nitro, amino, Ci ealkylamino, di(Cι-6alkyl)amino, Ci-βalkyl C2-6alkenyl, C2-ealkynyl, haloCi-ealkyl, hydroxy, Ci-βalkoxy, haloCi-ealkyl, thiol, SFβ, phenylCi-βalkyl and phenyl; L is a bond or Ci-ealkylene; R1 and R2 independently chosen from hydrogen and Ci-ealkyl; or R1 and R2 may, together, form a methylene or ethylene bridge; W is halogen, Ci-βalkyl, haloCi-βalkyl, Ci-βalkoxy or haloCi-βalkoxy; X is O, S or NR3 where R3 is hydrogen, hydroxy, Ci-βalkoxy, Ci-βalkyl, cyano, C3-6cycloalkyl, a siχ-membered saturated heterocycle containing one or two heteroatoms independently chosen from O, N and S, and R3 is, if possible, optionally substituted by Ci-βalkyl, Ci-βalkoxy, haloCi-βalkyl, haloCi-ealkoxy, halogen, amino, nitro, hydroxy, phenyl, a six-membered aromatic heterocycle containing up to three nitrogen atoms or a five-membered aromatic heterocycle containing up to four heteroatoms chosen from O, N and S, at most one heteroatom being O or S; or X, together with the atom to which it is attached, and Y, form an unsaturated five-membered ring together with A2; Y is a bond, Cι-4alkylene, NH or NH(CH2)ι-3; or a pharmaceutically acceptable salt thereof. A1 is preferably phenyl or a nitrogen containing heterocycle which is unsubstituted or substituted with one or two groups independently chosen from halogen, hydroxy, cyano, nitro, amino, Cι-4alkyl, haloCι-4alkyl, Ci-βalkoxy and haloCι-4alkoxy. More particularly A1 is phenyl, pyridinyl, pyrimidinyl or imidazolyl. Preferred substituents are halogen, Cι-4alkyl, Cι-4alkoxy and haloCι-4alkyl, such as fluorine, chlorine, methyl, methoxy and trifluoromethyl. Particular embodiments of A1 include 3-methylpyrid-2-yl, pyrid-2-yl, 1- methylimidazol-2-yl, 3-chloropyrid-2-yl, 3-fluoropyrid-2-yl, 3-methoxypyrid-2-yl, phenyl, pyrimidin-2-yl and 3-trifluoromethylpyrid-2-yl. Pyridyl, particularly pyrid-2-yl, especially substituted at the 3- position, preferably by methyl, is preferred. A2 is preferably a six-membered aromatic or heteroaromatic ring. A2 is preferably monosubstituted, particularly para to the point of attachment to Y. The substituent is preferably haloCi-βalkyl, Ci-βalkyl, SFs, phenyl, phenylCi-ealkyl, haloCi-ealkoxy, cyano or di(Cι-6alkyl)amino. More preferably the substituent is haloCι-4alkyl, Cι-4alkyl, SFs, phenyl, phenylCι-2alkyl, haloCι-4alkoxy, cyano or di(Cι-4alkyl)amino. Particular substituents include trifluoromethyl, isopropyl, 1,2,2,2-tetrafluoro-l-trifluoromethylethyl, tert-butyl, SFs, n-butyl, benzyl, phenyl, 2,2,2-trifluoroethyl, trifluoromethoxy, cyano and dimethylamino. A2 is preferably phenyl or pyridyl, particularly phenyl. Particular embodiments of A2 include 4-trifl.uoromethylphenyl, 4- isopropylphenyl, 4-(l,2,2,2-tetrafluoro- l-trifluoromethylethyl)phenyl, 4- benzylphenyl, 4-(pentafluoro-λe-sulfonyl)phenyl, biphenyl, 3- trifluoromethylpyrid-6-yl, 4-(2,2,2-trifluoroethyl)phenyl, 4- trifluoromethoxyphenyl, 4-cyanophenyl and 4-dimethylaminophenyl. One embodiment is 4-trifluoromethylphenyl. L is preferably a bond or Cι-3alkylene, such as ethylene. Most preferably L is a bond. R1 and R2 are preferably independently hydrogen, Cι-2alkyl or together form a methylene or ethylene bridge. More preferably they are hydrogen, methyl or an ethylene bridge. In one embodiment both are hydrogen. W is preferably halogen, Cι-4alkyl, haloCι-4alkyl, Cι-4alkoxy or haloCι-4alkoxy. More preferably W is halogen, Cι-2alkoxy or haloCι-2alkyl. Particular embodiments of W include fluorine, methoxy and fluoromethyl. X is preferably O, S, or NR3 where R3 is hydrogen, hydroxy, Ci-βalkyl,
Ci-βalkoxy, C3-6cycloalkyl, piperidinyl, piperazinyl or morpholinyl optionally substituted, if possible, by Ci-βalkyl, Ci-βalkoxy, halogen, haloCi-βalkyl, haloCι-6alkoxy, phenyl or pyridyl. More preferably X is O, S or NR3 where R3 is cyano or l-phenylpiperidin-4-yl. X may be O. Y is preferably a bond, NH, NHCH2, CH2 or CH2CH2. X, the atom to which X is attached, Y and A2 may together form an imidazole. Particular embodiments of the invention include: 4-fluoro-4-(3-methylpyridin-2-yl)-N-[4-trifl.uoromethylphenyl]piperidine-l- carboxamide;
4-fluoro-4(pyridin-2-yl)N-[4-trifluoromethylphenyl]piperidine-l-carboxamide; 4-fl.uoro-4(pyridine-2-yl)N [4-trifluoromethylbenzyl]piperidine-l-carboxamide; 2-{4-fl.uoro-l-[4-trifluoromethylbenzoyl]piperidin-4-yl}pyridine; 2-(4-fluoro-l-{[4-trifluoromethylphenyl]acetyl}piperidin-4-yl)pyridine; 2-(4-fluoro-l-{3-[4-trifluoromethylphenyl]propanoyl}piperidin-4-yl)pyridine
4-fluoro-4-(l-methyl-lH-imidazol-2-yl)-N-[4-trifluoromethylphenyl]piperidine-l- carboxamide;
4-methoxy-4-pyridin-2-yl-Λ^[4-trifluoromethylphenyl]piperidine-l-carboxamide; 4-methoxy-4-pyridin-2-yl-N-[4-trifluoromethylbenzyl]piperidine-l-carboxamide; 4-fluoro-N-(4-isopropylphenyl)-4-(3-methylpyridin-2-yl)piperidine-l-carboxamide;
4-fluoro-4-(3-methylpyridin-2-yl)-N{4-[l,2,2,2-tetrafluoro-l-trifluoromethylethyl] phenyl}piperidine-l-carboxamide;
N-(4-_Tert-butylphenyl)-4-fluoro-4-(3-methylpyridin-2-yl)piperidine-l- carboxamide;
4-fluoro-4-(3-methylpyridin-2-yl)-N-[4-(pentafluoro-λ6-sulfanyl)phenyl]piperidine-
1 -carboxamide;
N-(4-Butylphenyl)-4-fluoro-4-(3-methylpyridin-2-yl)piperidine-l-carboxamide;
Ν-(4-Benzylphenyl)-4-fluoro-4-(3-methylpyridin-2-yl)piperidine-l-carboxamide; A^-biphenyl-4-yl-4-fluoro-4-(3-methylpyridin-2-yl)piperidine-l-carboxamide;
4-fluoro-4-(3-methylpyridin-2-yl)-N-[5-trifluoromethylpyridin-2-yl]piperidine-l- carboxamide;
4-(3-chloropyridin-2-yl)-4-fluoro-N-[4-trifluoromethylphenyl]piperidine-l- carboxamide 4-fluoro-4-(3-fluoropyridin-2-yl)-N-[4-trifluoromethylphenyl]piperidine-l- carboxamide;
4-fluoro-4-(3-methoxypyridin-2-yl)-N-[4-trifluoromethylphenyl]piperidine-l- carboxamide!
4-fluoro-4-(3-methylpyridin-2-yl)-N-[4-trifluoromethylphenyl]piperidine-l- carbothioamide;
_V-cyano-4-fl.uoro-4-(3-methylpyridin-2-yl)-N-[4-trifluoromethylphenyl]piperidine-
1-carboximidamide;
4-fluoro-4-(3-methylpyridin-2-yl)-N-(l-phenylpiperidin-4-yl)-N:[4- trifluoromethylphenyl]piperidine-l-carboximidamide; 4-fluoro-4-phenyl-N-[4-trifluoromethylphenyl]piperidine-l-carboxamide;
(+/-)-(syn)-4-fluoro-2-methyl-4-(3-methylpyridin-2-yl)-Ν-[4- trifluoromethylphenyl] piperidine- 1-carboxamide!
4-(fluoromethyl)-4-pyridin-2-yl-N-[4-trifluoromethylphenyl]piperidine-l- carboxamide; syn- and ai2t_'-3-fl.uoro-3-pyridin-2-yl-N-[4-trifluoromethylphenyl]-8- azabicyclo[3.2.l]octane-8-carboxamide & 3-fluoro-3-pyridin-2-yl-N[4- trifluoromethylphenyl]-8-azabicyclo[3.2.l]octane-8-carboxamide;
4-fluoro-4-pyrimidin-2-yl-N-[4-trifluoromethylphenyl]piperidine-l-carboxamide;
4-fluoro-4-(3-phenylpropyl)-Nr-[4-trifluoromethylphenyl]piperidine-l-carboxamide; 2-[4-fluoro-4-(3-methylpyridin-2-yl)piperidin-l-yl]-6-trifluoromethyl-lH- benzimidazoleϊ
2-(4-fluoro-4-pyridin-2-ylpiperidin-l-yl)-6-(trifluoromethyl)-lj?J-benzimidazole;
4-fluoro-N- [4-trifluoromethylphenyl] -4- [3-trifluoromethylpyridin-2-yl]piperidine- 1-carboxamide;
4-fluoro-N-(4-methylphenyl)-4-(3-methylpyridin-2-yl)piperidine-l-carboxamide;
N-(4-ethylphenyl)-4-fluoro-4-(3-methylpyridin-2-yl)piperidine-l-carboxamide;
N-(4-chlorophenyl)-4-fluoro-4-(3-methylpyridin-2-yl)piperidine-l-carboxamide;
4-fluoro-4-(3-methylpyridin-2-yl)-N-[4-trifluoromethoxyphenyl]piperidine-l- carboxamide;
N-(4-cyanophenyl)-4-fluoro-4-(3-methylpyridin-2-yl)piperidine-l-carboxamide;
N-[4-dimethylaminophenyl]-4-fluoro-4-(3-methylpyridin-2-yl)piperidine-l- carboxamide; or a pharmaceutically acceptable salt thereof. As used herein, the term "alkyl" or "alkoxy" as a group or part of a group means that the group is straight or branched. Examples of suitable alkyl groups include methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl and t-butyl. Examples of suitable alkoxy groups include methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, s-butoxy and t-butoxy. "Alkylthio" shall be construed in an analogous manner. As used herein, the terms "haloCi-βalkyl" and "haloCi-βalkoxy" means a
Ci-βalkyl or Ci-βalkoxy group in which one or more (in particular, 1 to 3) hydrogen atoms have been replaced by halogen atoms, especially fluorine or chlorine atoms.
Preferred are fluoroCi-βalkyl and fluoroCi-βalkoxy groups, in particular, fluoroCι-3alkyl and fluoroCι-3alkoxy groups, for example, CF3, CH2CH2F,
CH2CHF2, CH2CF3, OCF3, OCH2CH2F, OCH2CHF2 or OCH2CF3, and most especially CF3 and OCF3. As used herein, the terms "alkenyl" and "alkynyl" as a group or part of a group means that the group is straight or branched. Examples of suitable alkenyl groups include vinyl and allyl. A suitable alkynyl group is acetylene or propargyl. When used herein, the term "halogen" means fluorine, chlorine, bromine and iodine. The most preferred halogens are fluorine and chlorine, especially fluorine. Examples of 6-merαbered heterocycles are pyridine, pyrimidine, pyrazine, pyridazine and triazine. Examples of 5-membered heterocycles are thiophene, furan, pyrrole, imidazole, pyrazole, oxazole, isoxazole, thiazole, isothiazole, 1,2,3-triazole, 1,2,4- triazole, oxadiazole, thiadiazole and tetrazole. In a further aspect of the present invention, the compounds of formula I may be prepared in the form of a pharmaceutically acceptable salt, especially an acid addition salt. For use in medicine, the salts of the compounds of formula I will be non-toxic pharmaceutically acceptable salts. Other salts may, however, be useful in the preparation of the compounds according to the invention or of their non-toxic pharmaceutically acceptable salts. Suitable pharmaceutically acceptable salts of the compounds of this invention include acid addition salts which may, for example, be formed by mixing a solution of the compound according to the invention with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, fumaric acid, p-toluenesulphonic acid, maleic acid, succinic acid, acetic acid, citric acid, tartaric acid, carbonic acid, phosphoric acid or sulphuric acid. A further salt is the acid addition salt with benzenesulfonic acid. Preferred pharmaceutically acceptable salts of the compounds of the present invention are the besylate salts. Salts of amine groups may also comprise quaternary ammonium salts in which the amino nitrogen atom carries a suitable organic group such as an alkyl, alkenyl, alkynyl or aralkyl moiety. Furthermore, where the compounds of the invention carry an acidic moiety, suitable pharmaceutically acceptable salts thereof may include metal salts such as alkali metal salts, e.g. sodium or potassium salts; and alkaline earth metal salts, e.g. calcium or magnesium salts. The salts may be formed by conventional means, such as by reacting the free base form of the compound of formula I with one or more equivalents of the appropriate acid in a solvent or medium in which the salt is insoluble, or in a solvent such as water which is removed in vacuo or by freeze drying or by exchanging the anions of an existing salt for another anion on a suitable ion exchange resin. The present invention also includes within its scope N-oxides of the compounds of formula I above. In general, such N-oxides may be formed on any available nitrogen atom. The N-oxides may be formed by conventional means, such as reacting the compound of formula I with oxone in the presence of wet alumina. The present invention includes within its scope prodrugs of the compounds of formula I above. In general, such prodrugs will be functional derivatives of the compounds of formula I which are readily convertible in vivo into the required compound of formula I. Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in "Design of Prodrugs", ed. H. Bundgaard, Elsevier, 1985. A prodrug may be a pharmacologically inactive derivative of a biologically active substance (the "parent drug" or "parent molecule") that requires transformation within the body in order to release the active drug, and that has improved delivery properties over the parent drug molecule. The transformation in vivo may be, for example, as the result of some metabolic process, such as chemical or enzymatic hydrolysis of a carboxylic, phosphoric or sulphate ester, or reduction or oxidation of a susceptible functionality. The present invention includes within its scope solvates of the compounds of formula I and salts thereof, for example, hydrates. The compounds according to the invention may have one or more asymmetric centres, and may accordingly exist both as enantiomers and as diastereoisomers. It is to be understood that all such isomers and mixtures thereof are encompassed within the scope of the present invention. Furthermore, the compounds of formula I may also exist in tautomeric forms and the invention includes within its scope both mixtures and separate individual tautomers. The compounds may exist in different isomeric forms such as syn- and a__t_'-isomers, all of which are encompassed by the present invention. The present invention further provides pharmaceutical compositions comprising one or more compounds of formula I in association with a pharmaceutically acceptable carrier or excipient. Preferably the compositions according to the invention are in unit dosage forms such as tablets, pills, capsules, powders, granules, sterile parenteral solutions or suspensions, metered aerosol or liquid sprays, drops, ampoules, auto- injector devices, suppositories, creams or gels; for oral, parenteral, intrathecal, intranasal, sublingual, rectal or topical administration, or for administration by inhalation or insufflation. Oral compositions such as tablets, pills, capsules or wafers are particularly preferred. For preparing solid compositions such as tablets, the principal active ingredient is mixed with a pharmaceutical carrier, e.g. conventional tabletting ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate or gums, and other pharmaceutical diluents, e.g. water, to form a solid pre-formulation composition containing a homogeneous mixture of a compound of the present invention, or a pharmaceutically acceptable salt thereof. When referring to these pre-formulation compositions as homogeneous, it is meant that the active ingredient is dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules. This solid pre-formulation composition is then subdivided into unit dosage forms of the type described above containing from 0.1 to about 500 mg of the active ingredient of the present invention. Favoured unit dosage forms contain from 1 to 500 mg, for example 1, 5, 10, 25, 50, 100, 300 or 500 mg, of the active ingredient. The tablets or pills of the novel composition can be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action. For example, the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former. The two components can be separated by an enteric layer that serves to resist disintegration in the stomach and permits the inner component to pass intact into the duodenum or to be delayed in release. A variety of materials can be used for such enteric layers or coatings, such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol and cellulose acetate. The liquid forms in which the novel compositions of the present invention may be incorporated for administration orally or by injection include aqueous solutions, suitably flavoured syrups, aqueous or oil suspensions, and flavoured emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil or peanut oil, as well as elixirs and similar pharmaceutical vehicles. Suitable dispersing or suspending agents for aqueous suspensions include synthetic and natural gums such as tragacanth, acacia, alginate, dextran, sodium carboxymethylcellulose, methylcellulose, polyvinyl-pyrrolidone or gelatin. In the treatment of painful conditions such as those listed below, a suitable dosage level is about 1.0 mg to 15 g per day, preferably about 5.0 mg to 1 g per day, more preferably about 5 mg to 500 mg per day, especially 10 mg to 100 mg per day. The compounds may be administered on a regimen of 1 to 4 times per day. It will be appreciated that the amount of a compound of formula I required for use in any treatment will vary not only with the particular compounds or composition selected but also with the route of administration, the nature of the condition being treated, and the age and condition of the patient, and will ultimately be at the discretion of the attendant physician. The invention further provides a compound of formula I as defined above, or a pharmaceutically acceptable salt thereof, for use in treatment of the human or animal body. Preferably, said treatment is for a condition which is susceptible to treatment by modulation (preferably antagonism) of VRl receptors. The compounds of the present invention will be of use in the prevention or treatment of diseases and conditions in which pain and/or inflammation predominates, including chronic and acute pain conditions. Such conditions include rheumatoid arthritis! osteoarthritis; post-surgical pain; muscukrskeletal pain, particularly after trauma; spinal pain; myofascial pain syndromes! headache, including migraine, acute or chronic tension headache, cluster headache, temporomandibular pain, and maxillary sinus pain; ear pain! episiotomy pain; burns, and especially primary hyperalgesia associated therewith; deep and visceral pain, such as heart pain, muscle pain, eye pain, orofacial pain, for example, odontalgia, abdominal pain, gynaecological pain, for example, dysmenorrhoea, pain associated with cystitis and labour pain, chronic pelvic pain, chronic prostatitis and endometriosis; pain associated with nerve and root damage, such as pain associated with peripheral nerve disorders, for example, nerve entrapment and brachial plexus avulsions, amputation, peripheral neuropathies, tic douloureux, atypical facial pain, nerve root damage, and arachnoiditis; itching conditions including pruritis, itch due to hemodialysis, and contact dermatitis; pain (as well as broncho-constriction and inflammation) due to exposure (e.g. via ingestion, inhalation, or eye contact) of mucous membranes to capsaicin and related irritants such as tear gas, hot peppers or pepper spray; neuropathic pain conditions such as diabetic neuropathy, chemotherapy-induced neuropathy and post-herpetic neuralgia; "non-painful" neuropathies; complex regional pain syndromes; pain associated with carcinoma, often referred to as cancer pain; central nervous system pain, such as pain due to spinal cord or brain stem damage, low back pain, sciatica and ankylosing spondylitis; gout; scar pain! irritable bowel syndrome; inflammatory bowel disease; urinary incontinence including bladder detrusor hyper-reflexia and bladder hypersensitivity; respiratory diseases including chronic obstructive pulmonary disease (COPD), chronic bronchitis, cystic fibrosis, asthma and rhinitis, including allergic rhinitis such as seasonal and perennial rhinitis, and non-allergic rhinitis and cough; autoimmune diseases; and immunodeficiency disorders. The compounds of the present invention may also be used to treat depression. They may also be used to treat gastro-oesophageal reflux disease (GERD), particularly the pain associated with GERD. Thus, according to a further aspect, the present invention provides a compound of formula I for use in the manufacture of a medicament for the treatment or prevention of physiological disorders that may be ameliorated by modulating VRl activity. The present invention also provides a method for the treatment or prevention of physiological disorders that may be ameliorated by modulating VRl activity, which method comprises administration to a patient in need thereof of an effective amount of a compound of formula I or a composition comprising a compound of formula I. According to a further or alternative aspect, the present invention provides a compound of formula I for use in the manufacture of a medicament for the treatment or prevention of a disease or condition in which pain and/or inflammation predominates. The present invention also provides a method for the treatment or prevention of a disease or condition in which pain and/or inflammation predominates, which method comprises administration to a patient in need thereof of an effective amount of a compound of formula I or a composition comprising a compound of formula I. According to a further aspect of the present invention, it may be desirable to treat any of the aforementioned conditions with a combination of a compound according to the present invention and one or more other pharmacologically active agents suitable for the treatment of the specific condition. The compound of formula I and the other pharmacologically active agent(s) may be administered to a patient simultaneously, sequentially or in combination.
Thus, for example, for the treatment or prevention of pain and/or inflammation, a compound of the present invention may be used in conjunction with other analgesics, such as acetaminophen (paracetamol), aspirin and other NSAIDs, including selective cyclooxygenase-2 (COX-2) inhibitors, as well as opioid analgesics, especially morphine, NR2B antagonists, bradykinin antagonists, anti-migraine agents, anticonvulsants such as oxcarbazepine and carbamazepine, antidepressants (such as TCAs, SSRIs, SNRIs, substance P antagonists, etc.), spinal blocks, gabapentin, pregabalin and asthma treatments (such as &2_adrenergic receptor agonists or leukotriene D4 antagonists (e.g. montelukast). Specific anti-inflammatory agents include diclofenac, ibuprofen, indomethacin, nabumetone, ketoprofen, naproxen, piroxicam and sulindac, etodolac, meloxicam, rofecoxib, celecoxib, etoricoxib, parecoxib, valdecoxib and tilicoxib. Suitable opioid analgesics of use in conjunction with a compound of the present invention include morphine, codeine, dihydrocodeine, diacetylmorphine, hydrocodone, hydromorphone, levorphanol, oxymorphone, alfentanil, buprenorphine, butorphanol, fentanyl, sufentanyl, meperidine, methadone, nalbuphine, propoxyphene and pentazocine; or a pharmaceutically acceptable salt thereof. Suitable anti-migraine agents of use in conjunction with a compound of the present invention include CGRP-antagonists, ergotamines or 5ΗTι agonists, especially sumatriptan, naratriptan, zolmatriptan or rizatriptan. Therefore, in a further aspect of the present invention, there is provided a pharmaceutical composition comprising a compound of the present invention and an analgesic, together with at least one pharmaceutically acceptable carrier or excipient. In a further or alternative aspect of the present invention, there is provided a product comprising a compound of the present invention and an analgesic as a combined preparation for simultaneous, separate or sequential use in the treatment or prevention of a disease or condition in which pain and/or inflammation predominates. The compounds of formula I in which Y is NH or NH(CH2)ι-3 can be made by reacting a compound of formula II with a compound of formula III:
Figure imgf000014_0001
(ID (III)
wherein X1 is O or S, P is H or a Cι-6alkoxycarbonyl group such as tert- butoxycarbonyl and A1, A2, L, R1, R2 and W are as defined above.
The reaction is generally carried out in a solvent such as dichloromethane in the presence of a base such as triethylamine at about room temperature for about one hour. The resulting product can be converted into a compound of formula I in which X is NR3 by reacting with a compound of formula VIII:
R3NH2 (VIII)
in which R3 is as defined above, in the presence of a catalyst such as silver acetate in a solvent such as acetonitrile at about 140°C for about 10 minutes in a microwave or for several hours at reflux. The compound of formula II in which W is OH can be made by reacting a compound of formula VI with a compound of formula VII:
Figure imgf000014_0002
(VI) (VII)
wherein A1, R1, R2 and P are as defined above and L1 is a leaving group such as H or Br. The compound of formula VI is first converted to its anion by reacting with a strong base such as N-butyl lithium in hexanes and then reacted with the compound of formula VII generally in a solvent such as THF between -78°C and room temperature for several hours. The resulting group W can be converted into other groups W by standard methods known in the art. For example a hydroxy group can be converted to a fluorine atom by reacting with diethylaminosulphur trifluoride in a solvent such as dichloromethane at a temperature between -78°C and room temperature for about two hours. A hydroxy group can be converted to an alkoxy group by reacting first with a strong base such as sodium hydride in a solvent such as a mixture of tetrahydrofuran and dimethyl formamide for about two hours followed by addition of the appropriate alkyl iodide and leaving to react for about 3 days. Compounds of formula II in which W is CN can also be made by reacting a compound of formula X with a compound of formula XI:
A1-CH2-CN (C1CH2CH2)2NP (X) (XI)
wherein A1 and R are as defined above in the presence of a strong base such as sodium hydride in a solvent such as anhydrous dimethylformamide at about 60°C for about 5/4 hours. The cyano group can be converted to an ester using hydrogen chloride gas in anhydrous methanol. This can be reduced to a hydroxymethyl group using a reagent such as lithium aluminium hydride in a solvent such as tetrahydrofuran at about -30°C for about one hour. This group can be converted to a fluoromethyl group using a reagent such as diethylaminosulphur trifluoride in a solvent such as anhydrous ethyl acetate at between -78°C and room temperature for several hours. Compounds of formula III in which X1 is O can be made by reacting the corresponding amine with triphosgene followed by a base such as triethylamine in a solvent such as dichloromethane for about one hour. Compounds of formula III in which X1 is O can be made by reacting the corresponding carboxylic acid with an azide such as diphenyl phosphoryl azide in the presence of a base such as triethylamine at about 90°C for about 3 hours so that a Curtius rearrangement occurs. Compounds of formula "VTI can be made by hydrogenating a compound of formula IX:
Figure imgf000016_0001
(IX)
wherein R1, R2 and P are as defined above by stirring with a reducing agent such as zinc powder in a solvent such as acetic acid at reflux for about 18 hours. In an alternative process, compounds of formula I in which Y is a bond or Cι-4alkylene can be made by reacting a compound of formula II with a compound of formula IV:
Figure imgf000016_0002
(IV)
wherein both X*s are O or S, Y is a bond or Cι-4alkylene and A2 is as defined above. The reaction is generally carried out in a solvent such as tetrahydrofuran at about 70°C for several hours. The compound of formula IV may be pre-reacted with an activating agent such as carbonyldiimidazole in a solvent such as tetrahydrofuran for about 3 hours at about 70°C. In a further process, compounds of formula I in which X, together with the atom to which it is attached, and Y, form an unsaturated five membered ring together with A2 can be made by reacting a compound of formula II with a compound of formula V:
Figure imgf000017_0001
(V)
wherein X, together with the atom to which it is attached and Y, form an unsaturated five membered ring together with A2. The reaction is generally carried out in a solvent such as ethanol with heating to about 160°C for about 10 minutes preferably in a microwave. Where the synthesis of intermediates and starting materials is not described these compounds are commercially available or can be made from commercially available compounds by standard methods. During any of the above synthetic sequences it may be necessary and or desirable to protect sensitive or reactive groups on any of the molecules concerned. This may be achieved by means of conventional protecting groups, such as those described in Protective Groups in Organic Chewistry, ed. J.F.W.
McOmie, Plenum Press, 1973; and T.W. Greene and P.G.M. Wuts, Protective Groups in Organic Synthesis, John Wiley & Sons, 1991. The protecting groups may be removed at a convenient subsequent stage using methods known from the art. The following Examples serve to illustrate the preparation of compounds of the present invention.
COMMON INTERMEDIATES
Description Example 1 Tart-butyl 4-hvdroxy-4-(3-methylpyridin-2- vDpiperidine- 1-carboxylate N-butyl lithium (15.63ml, 1.6M in hexanes) was added dropwise to a stirred solution of 2-bromo-3-methyl pyridine (4.3g, 25mmol) in THF (35ml) at -78°C over 40 minutes. The anion formed went from orange to brown. After 30 minutes at -78°C, l-tertbutoxycarbonyl-4-piperidone (5g) in THF (30ml) was added dropwise over 20 minutes. The reaction mixture was allowed to warm to room temperature overnight. Water (50ml) was added and the organic layer was separated. The aqueous was extracted using ethyl acetate (2x50ml). The organics were combined, dried (Na2SO4) and evaporated. Purification by column chromatography on silica using 5-10% ethyl acetate in isohexane yielded the desired product (l.72g).
1H NMR δ(ppm) 400MHz (CDC13): 1.44 (2 H, d, J = 12.9Hz), 1.50 (9 H, s), 2.27- 2.34 (2 H, m), 2.50 (3 H, s), 3.26-3.4 (2 H, br m), 4.0-4.2 (2 H, br m), 6.63 (l H, s), 7.18 (1 H, dd, J = 4.7, 7.8Hz), 7.50(lH, dd, J=1.2, 7.8Hz), 8.38 (l H, dd, J = 1.2, 4.7Hz). MSp m/z for MH+ =293.
Description Example 2 _pert-butyl 4-fluoro-4-(3-methylpyridin-2-yl)piperidine-l- carboxylate
Description Example 1 (4.47g, lδmmol) in dichloromethane (150ml) was cooled to
-78°C and excess diethylaminosulphur trifluoride (ll.lδg, 69mmol) in dichloromethane (50ml) was added dropwise to the stirred solution. The reaction was warmed to room temperature over 2 hours. Water (50ml) was added and the organic layer separated. The aqueous was extracted with dichloromethane
(2x50ml). The organics were combined, dried (Na2SO4) and evaporated.
Purification by column chromatography on silica using 10-100% ethyl acetate in isohexane yielded the desired product (2.65g).
1H NMR δ (ppm) 400MHz(CDCl3): 1.48 (9 H, s), 1.95-2.1 (2H, br m) 2.15-2.45 (2H, br m) 2.50 (3 H, d, J = 5.9Hz), 3.15-3.3 (2 H, br m), 4.0-4.2 (2 H, br m), 7.12
(1 H, dd, J = 4.7, 7.8Hz), 7.46 (l H, dd, J = 1.2, 6.7Hz), 8.35 (l H, d, J = 4.7Hz).
MSp m/z for MH+ =295.
Description Example 3 2-(4-Fluoropiperidin-4-yl)-3-methylpyridine Description Example 2 (l.44g, 4.9mmol) in dichloromethane (20ml) was treated with trifluoroacetic acid (5ml) and stirred at room temperature for 3 hours. The reaction mixture was evaporated and purified using a strong cation exchange cartridge to give the desired product (710mg).
1H NMR δ (ppm) 400MHz(CDC13): 2.01-2.08 (2 H, m), 2.17-2.35 (2 H, m), 2.50 (3 H, d, J = 5.5Hz), 3.04 - 3.11 (4 H, m), 7.11 (l H, dd, J = 4.7, 7.4Hz), 7.45 (l H, dd,
J = 7.4, 0.8Hz), 8.37 (l H, d, J = 4.7Hz). MSp m/z for MH+ =195.
Description Example 4 2-(4-Fluoropiperidin-4-yl)pyridine
The title compound was prepared in analogous fashion to Description Example 3. IH NMR δ (ppm) 400MHz (CDC13): 1.84-1.91 (2 H, m), 2.14-2.22 (l H, m), 2.24- 2.32 (1 H, m), 3.04-3.10(4 H m), 7.18-7.22 (l H, ), 7.56 (l H, dd, J = 1.2, 7.8Hz), 7.70-7.74 (1 H, m), 8.56 (l H, m). MSp m/z for MH+ =181.
Description Example 5 -Tert-butyl 4-hvdroxy-4-(l-methyl- lH-imidazol-2- yl)piperidine-l-carboxylate N-butyl lithium (6.25ml,1.6M in hexanes) was added dropwise to a solution of 1- methyhmidazole in THF (15ml) at -78°C. After 30 minutes at this temperature, l-tertbutoxycarbonyl-4-piperidone (2g) in THF (15ml) was added dropwise. The reaction mixture was allowed to warm to room temperature overnight. Water (50ml) was added and the organics were separated. The aqueous was extracted using ethyl acetate (2x50ml). The organics were combined, dried (Na2SO4) and evaporated. Purification by column chromatography on silica using 5% methanol in dichloromethane as the eluant gave the desired product (2g). IH NMR δ (ppm) 400MHz (CDC13): 1.46 (9 H, s), 1.77-1.85 (2 H, m ), 2.05-2.18 (2 H, br m), 3.18 (l H, br s), 3.26-3.37 (2 H, br m), 3.8-3.93 (2H, br m), 3.84 (3H,s), 6.81 (2 H, s). MSp m/z for MH+ =282.
Description Example 6 Terfcbutyl 4-methoxy4-(pyridin-2-yl)piperidine- 1- earboxylate
Description Example 1 (557mg, 2mmol) in THF (5ml) was treated with sodium hydride (56mg, 95% dry, 2.2mmol) and stirred at room temperature for 20 minutes. Dimethylformamide (5ml) was added to aid solubility of the anion formed. Iodomethane (l31μl) was added. After 2 hours and 4 hours, further iodomethane (50 μl) was added. The reaction was stirred for 72 hours. Water
(20ml) was added and the aqueous was extracted using ethyl acetate (3 x 20ml). The combined organics were dried (Na2SO4), filtered and evaporated. The compound was purified by column chromatography using 20% ethyl acetate in isohexane as eluant to give the desired material (250mg). IH NMR δ (ppm) 400MHz (CDC13): 1.46 (9 H, s), 1.95-1.99 (2 H, m), 2.05-2.12 (2 H, m), 3.06 (3 H, s), 3.18-3.24 (2 H, m), 3.92-3.95 (2 H, m), 7.20 (l H, dd, J = 1.2, 12.1Hz), 7.48-7.50 (1 H, m), 7.69-7.73 (l H, m), 8.57-8.59 (l H, m). FINAL PRODUCTS
Example 1 4-Fluoro-4-(3-methylpyridin-2-yl)-N-[4- trifluoromethylphenyl] piperidine- 1-carboxamide Trifluoroacetic acid (2ml) was added to a stirred solution of Description Example 2 (δlOmg, 1.73mmol) in dichloromethane (8ml). After 1 hour, the reaction was complete and the solvent was removed by evaporation. The residue was dissolved in dichloromethane (lOml), treated with triethylamine (l.25ml) followed by 4- trifluoromethylphenyl isocyanate (324mg, 1.73mmol) and stirred at room temperature for 1 hour. The reaction mixture was evaporated and purified by column chromatography on silica using 20-33% ethyl acetate in isohexane to give the desired product (470mg).
IH ΝMR δ (ppm) (CDC13): 2.13-2.20 (2 H, m), 2.37-2.49 (2 H, m), 2.52 (3 H, d, J = 5.9Hz), 3.38-3.48 (2 H, m), 4.04-4.11 (2 H, m), 6.57 (l H, s), 7.15 (l H, dd, J = 4.7, 7.8Hz), 7.48-7.56 (5 H, m), 8.35 (l H, d, J = 4.7Hz). MSp m/z for MH+ =382.
Example 2 4-Fluoro-4(pyridin-2-yl)N-[4-trifluoromethylphenyl]piperidine-l- carboxamide Using Description Example 4 and the procedure shown in Example 1, the title compound was obtained.
IH ΝMR δ (ppm) 400MHz(CDC13): 1.96-2.04 (2 H, m), 2.32-2.50 (2 H, m), 3.37- 3.44 (2 H, m), 4.09-4.13 (2 H, m), 6.57 (l H, s), 7.22-7.25 (l H, m), 7.48-7.60 (5 H, m), 7.73-7.78 (l H, m), 8.54-8.56 (l H, m). MSp m/z for MH+ =368.
Example 3 4-Fluoro-4(pyridine-2- yl)N- [4-trifluoromethylbenzyl] piperidine- 1 - carboxamide
Using Description Example 4, (4-trifluoromethylbenzyl)isocyanate and the procedure shown in Example 1, the title compound was obtained.
IH ΝMR δ (ppm) 400MHz (DMSO): 1.81-1.89 (2 H, m), 2.05-2.23 (2 H, m), 3.06- 3.14 (2 H, m), 4.00-4.06 (2 H, m), 4.35 (2 H, d, J = 5.9Hz), 7.31-7.38 (2 H, m), 7.49
(2 H, d, J = 7.8Hz), 7.59 (l H, dd, J = 1.2, 7.8Hz), 7.68 (2 H, d, J=7.8Hz), 7.86-7.90
(1 H, m), 8.56-8.58 (l H, m). MSp m/z for MH+ =382. Example 4 2-{4-Fluoro-l-[4-trifluoromethylbenzoyllpiperidin-4-yl}pyridine 4-trifluoromethylbenzoic acid (38mg, 0.2mmol) in THF (lml) was treated with l,l'-carbonyldiimidazole (32mg, 0.2mmol) and heated at 70 °C for 3 hours. Description Example 4 in THF (lml) was added and the reaction mixture was heated at 70 °C overnight. Following evaporation, the compound was purified by column chromatography on silica using 33% ethyl acetate in isohexane as the eluant gave the desired product (25mg).
IH NMR δ (ppm) 400MHz (CDC13) 1.8-2.1 (2 H, m), 2.25-2.51 (2 H, m), 3.20- 3.3.35 (1 H, m), 3.34-3.59 (lH, br m), 3.61-3.76 (lH, br m), 4.71-4.85 (l H, br m), 7.24-7.27 (l H, m), 7.57-7.61 (3 H, m), 7.70 (2 H, d, J=7.8Hz), 7.74-7.79 (l H, m), 8.57-8.59 (1 H, m). MSp m/z for MH+ =353.
Example 5 2-(4-Fluoro-l-{f4-trifluoromethylphenyl]acetyl}piperidin-4- vQpyridine Using Description Example 4, 4-trifluoromethylphenyl acetic acid and the procedure shown in Example 4, the title compound was obtained. IH NMR δ (ppm) 500MHz (CDC13)l.86-2.0 (2 H, m), 2.13-2.33 (2 H, m), 3.03-3.09 (1 H, ), 3.46-3.52 (l H, m), 3.83 (2 H, d, J = 4.2Hz), 3.85-3.89 (l H, m), 4.65-4.72 (IH, m), 7.21-7.23 (l H, m), 7.40 (2 H, d, J = 8.1Hz), 7.55 (l H, d, J = 7.8Hz), 7.60 (2 H, d, J = 8.1Hz), 7.71-7.77 (l H, m), 8.53 (l H, d, J = 4.9Hz). MSp m/z for MH+ =367.
Example 6 2-(4-Fluoro-l-{3-[4-trifluoromethylphenyllpropanoyl}piperidin-4- vOpyridine Using Description Example 4, 4-trifluoromethylhydrocinnamic acid and the procedure shown in Example 4, the title compound was obtained. IH NMR δ (ppm) 360MHz (CDC13): 1.88-1.96 (2 H, m), 2.12-2.33 (2 H, m), 2.69 (2 H, t, J = 7.7Hz), 2.98-3.09 (3 H, m), 3.41-3.49 (l H, m), 3.79-3.84 (l H, m), 4.66- 4.71 (1 H, m), 7.21-7.24 (l H, m), 7.36 (2 H, d, J = 8.1Hz), 7.55 (3 H, d, J = 8.1Hz), 7.71-7.76 (l H, m), 8.54 (l H, d, J = 3.9Hz). MSp m/z for MH+ =381. Example 7 4-Fluoro-4-(l-methyl-lH-imidazol-2-yl)-N-[4-trifluoromethylphenyll piperidine- l'carboxamide The title compound was prepared in analogous fashion to Example 1 from Description Example 5. IH NMR δ (ppm) 400MHz (DMSO): 2.10-2.27 (4 H, m), 3.29-3.37 (2 H, m), 3.77 (3 H, d, J = 2.0Hz), 3.94-4.00 (2 H, m), 6.83 (l H, s), 7.17 (l H, s), 7.59 (2 H, d J=8.6Hz), 7.69 (1 H, d J=8.6Hz), 9.01 (l H, s). MSp m/z for MH+ =371.
Example 8 4-methoxy-4-pyridin-2-yl-N-[4-trifluoromethylphenyl]piperidine-l- carboxamide
Description Example 6 (250mg, 0.86mmol) in dichloromethane (4ml) was treated with trifluoroacetic acid (lml) and stirred at room temperature overnight. The reaction mixture was evaporated, and the amine was isolated using a strong cation exchange cartridge as the free base (I86mg). This amine (83mg) in dichloromethane (lml) was treated with 4-trifluoromethylphenylisocyanate (62ul, 0.43mmol) and stirred at room temperature for 1 hour. Following evaporation the compound was purified by column chromatography on silica using 50% ethyl acetate in isohexane as the eluant to give the desired compound (l44mg). IH NMR δ (ppm) 360MHz (CDC13): 2.04 -2.25 (4 H, m), 3.10 (3 H, s), 3.38-3.46 (2 H, m), 3.93 (2 H,m), 6.54 (l H, s), 7.22 (l H, dd, J = 5.1, 7.2Hz), 7.53 (5 H, m), 7.71-7.76 (1 H, m), 8.58 (l H, dd, J = 0.7, 4.2Hz). MSp m z for MH+ =380.
Example 9 4-Methoxy-4-pyridin-2-yl-N'-[4-trifluoromethylbenzyl]piperidine-l- carboxamide The title compound was obtained using the procedure shown in Example 8 and employing Description Example 6 and [4-trifluoromethylbenzyl]isocyanate. IH NMR δ (ppm) 360MHz (CDC13): 2.02 -2.18 (4 H, m), 3.07 (3 H, s), 3.28-3.36 (2 H, m), 3.79-3.83 (2 H, m), 4.50 (2 H, d, J = 5.6Hz), 4.84-4.87 (l H, m), 7.18-7.22 (l H, m), 7.43 (2 H, J=8.lHz) 7.49 (lH, J=8Hz), 7.58 (2 H, J=8.1Hz), 7), 7.69-7.74 (l H, m), 8.58 (l H, dd, J = 1.1, 4.2Hz). MSp m/z for MH+ =394. Example 10 4-Fluoro-N-(4-isopropylphenyl)-4-(3-methylpyridin-2-yl)piperidine- 1-carboxamide 4-isopropylphenylisocyanate (40.3mg, 0.25mmol) in dichloromethane (lml) was treated with Description Example 3 (48.5mg, 0.25mmol) in dichloromethane 5 (lml) and stirred overnight at room temperature. The compound was purified by column chromatography on silica using 20-40% ethyl acetate in isohexane the eluant to give the desired compound (75mg). IH NMR δ (ppm) 400MHz (CDC13): 1.23 (6 H, d, J = 6.7Hz), 2.10-2.17 (2 H, m), 2.35-2.52 (5 H, m), 2.83-2.90 (l H, m), 3.37-3.44 (2 H, m), 4.02-4.06 (2 H, m), 6.350 (1 H, s), 7.12-7.16 (3 H m), 7.26 (2 H, d, J=6.8Hz), 7.28 (l H, s), 7.48 (l H, dd, J = 0.8, 7.0Hz), 8.35 (l H, d, J = 4.7Hz). MSp m/z for MH+ =356.
Example 11 4-Fluoro-4-(3-methylpyridin-2-yl)-7yr-{4-[l.2.2.2-tetrafluoro-l- trifluoromethylethyll phenyllpiperidine- 1 -carboxamide5 4-(l,2,2,2-tetrafluoro-l-trifluoromethylethyl)phenylamine (l31mg, O.δmmol) in dichloromethane (5ml) was treated with triphosgene (49mg, 0.167mmol) followed by triethylamine (50. δmg,0.δmmol) .After one hour Description Example 3 (97mg, O.δmmol) in dichloromethane (lml) was added and the reaction mixture was stirred at room temperature overnight. Water (2ml) was added and the organics0 were separated using a phase separation cartridge. The compound was purified using a strong cation exchange cartridge followed by column chromatography on silica using 20% ethyl acetate in hexane as the eluant to give the desired compound (lδmg). IH NMR δ (ppm) 400MHz (CDC13): 2.12-2.2 (2 H, ), 2.37-2.64 (δ H, m)3.42-3.49δ (2 H, m), 4.03-4.1 (2 H, m), 6.67 (l H, s), 7.15 (l H, dd, J = 4.5, 7.6Hz), 7.49 - 7.62 (δH, m). 8.36 (l H, d, J = 4.7Hz). MSp m/z for MH+ =482.
Example 12 N-(4- Tert-butylphenyl)-4-fluoro-4-(3-methylpyridin-2-yl)piperidine- 1 -carboxamide0 The title compound was obtained using the procedure shown in Example 10 using 4-tert-butylphenyl isocyanate and Description Example 3. IH ΝMR δ (ppm) 400MHz (CDC13): 1.30 (9 H, s), 2.10-2.17 (2 H, m), 2.35-2.52 (δ H, ), 3.37-3.46 (2 H, ), 4.02-4.06 (2 H, m), 6.34 (l H, s), 7.14 (l H, dd, J = 4.7, 7.8Hz), 7.26-7.33 (4 H, m), 7.48 (l H, d, J = 7.8Hz), 8.35 (l H, d, J = 4.3Hz). MSp m/z for MH+ =370.
Example 13 4-Fluoro-4-(3-methylpyridin-2-yl)--¥-r4-(pentafluoro-λβ-sulfanyl) phenyll piperidine- 1-carboxamide
The title compound was obtained using the procedure shown in example 17 using [4-(pentafluoro-λ6-sulfanyl)phenyl]amine and Description Example 3. H NMR δ (ppm) 400MHz (DMSO): 2.06-2.12 (2 H, m), 2.17-2.34 (2 H, m), 2.48 (3 H, d, J = 5.5Hz), 3.19-3.27 (2 H, m), 4.1-4.18 (2 H, m) 7.28 (l H, dd, J = 4.6, 7.6Hz), 7.63-7.70 (3 H, m), 7.75 - 7.78 (2 H, m), 8.37 (l H, d, J = 4.6Hz), 9.10 (l H, s). MSp m/z for MH+ =440.
Example 14 A^-(4-Butylphenyl)-4-fluoro-4-(3-methylpyridin-2-yl)piperidine-l- carboxamide The title compound was obtained using the procedure shown in Example 10 using 4-n-butylphenyl isocyanate and Description Example 3.
IH NMR δ (ppm) 400 MHz (CDC13): 0.91 (3 H, t, J = 7.2Hz), 1.29-1.39 (2 H, m), 1.53-1.61 (2 H, m), 2.10-2.17 (2 H, m), 2.34-2.58 (7 H, m), 3.37-3.44 (2 H, m), 4.02- 4.06 (2 H, m), 6.35 (l H, s), 7.08-7.14(3H , m), 7.24-7.28 (2 H, m), 7.48 (l H, dd, J = 7.0, 0.8Hz), 8.35 (l H, d, J = 4.7Hz). MSp m/z for MH+ =370.
Example 15 N-(4-Benzylphenyl)-4-fluoro-4-(3-methylpyridin-2-yl)piperidine-l- carboxamide The title compound was obtained using the procedure shown in Example 10 using 4-benzylphenyl isocyanate and Description Example 3.
IH NMR δ (ppm) 400MHz (CDC13): 2.10-2.17 (2 H, m), 2.34-2.48 (2 H, m), 2.51 3 H, d, J = 5.6Hz), 3.37-3.44 (2 H, m), 3.94 (2 H, s), 4.01-4.06 (2 H, m), 6.37 (l H, s), 7.10-7.20 (6 H, m), 7.25-7.30 (4 H, m), 7.47 (l H, dd, J = 7.4, 0.8Hz), 8.35 (l H, d, J = 4.7Hz). MSp m/z for MH+ =404.
Example 16 N"-biphenyl-4-yl-4-fluoro-4-(3-methylpyridin-2-yl)piperidine-l- carboxamide The title compound was obtained using the procedure shown in example 16 using 4-biphenyl isocyanate and Description Example 3. IH NMR δ (ppm) 400MHz (DMSO): 2.04-2.13(2 H, m), 2.18-2.35 (2 H, m), 2.48- 2.51(3 H, m), 3.20-3.27 (2 H, m), 4.13-4.16 (2 H, m, 7.26-7.32 (2 H, m), 7.40-7.45 (2 H, m ), 7.55-7.65 (7 H, m), 8.38 (l H, d, J = 4.7Hz), 8.73 (l H, s) MSp m/z for MH+ =390.
Example 17 4-Fluoro-4-(3-methylpyridin-2-yl)-N-[5-trifluoromethylpyridin-2- yl]piperidine-l-carboxamide 5-Trifluoromethylpyridine-2-carboxyHc acid (I91mg, lmmol), diphenyl phosphoryl azide (275mg, lmmol) and triethylamine(202mg, 2mmol) was heated at 90 °C for 3 hours. Description Example 3 (l95mg, lmmol) was added to the reaction mixture and stirred at room temperature for 72 hours. The reaction mixture was evaporated, partitioned between water (2ml) and dichloromethane (5ml) in a phase separation cartridge. The aqueous phase was washed with more dichloromethane and the combined organics were evaporated. The compound was purified by mass-triggered HPLC to give the desired compound (27mg).
IH NMR δ (ppm) 400MHz(CDC13): 2.12-2.22 (2 H, m), 2.36-2.52 (5 H, m), 3.42- 3.50 (2 H, m), 4.07-4.13 (2 H, m), 7.14 (l H, dd, J = 4.5, 7.6Hz), 7.43-7.51 (2 H, m), 7.87 (1 H, dd, J = 2.3, 8.6Hz), 8.19 (l H, d, J = 9.0Hz), 8.35 (l H, d, J = 4.7Hz), 8.46 (1 H, s). MSp m/z for MH+ =383.
Example 18 4- (3 - Chlorop yridin- 2 - yl) -4-fluoro- N- [4-trifluoromethylphenyll piperidine- 1 -carboxamide l,4-diazabicyclo[2.2.2]octane (3.08g,27.5mmol) in diethyl ether (llOml) was treated with n-butyl lithium in hexanes (17.2ml, 1.6M, 25mmol) at -40 °C keeping the temperature in the range -40 °C to -30 °C, and stirred in this temperature range for 1 hour. The reaction was cooled to -65 °C and 3-chloropyridine (2.84g, 25mmol) was added and stirred at this temperature for 1 hour. The mixture was cooled to -78 °C and l-tertbutoxycarbonyl-4-piperidone (4.98g, 25mmol) in diethyl ether (50ml) was added dropwise. After 1 hour at -78 °C, the reaction was allowed to warm to -50 °C over 2 hours. Saturated aqueous ammonium chloride (50ml) was added and the aqueous was extracted using ethyl acetate (4x50ml). The combined organics were dried over sodium sulphate and evaporated. Column chromatography on silica using 5- 20% ethyl acetate in isohexane as eluant gave ter^butyl 4-hydroxy-4-(3-chloropyridin-2-yl)piperidine-l-carboxylate contaminated with l-tertbutoxycarbonyl-4-piperidone (3.31g). This mixture (l.9g) was converted to the desired compound (δlOmg) using the chemistry described in Description Example 2 and Example 1.
IH NMR δ (ppm) 400MHz (CDC13 ) 2.32-2.50 (4 H, m), 3.46-3.62 (2H, m), 4.02- 4.09 (2 H, m), 6.57 (l H, s), 7.22-7.26 (l H, m), 7.48-7.66 (4 H, m), 7.76 (l H, dd, J = 1.4, 8.0Hz), 8.44-8.46 (l H, m). MSp m/z for MH+ =402.
Example 19 4-Fluoro-4-(3-fluoropyridin-2-yl)-A/-f4-trifluoromethylphenyl1 piperidine- l'carboxamide The title compound was obtained using the chemistry described in Example 18, using 3-fluoropyridine as the starting material.
H NMR δ (ppm) 400MHz (CDC13): 2.27-2.45 (4 H, m), 3.46-3.53 (2 H, m), 4.02-
4.07 (2 H, m), 6.67 (l H, s), 7.31-7.38 (l H, m), 7.44-7.56 (5 H, m), 8.39 (l H, d, J =
4.7Hz). MSp m/z for MH+ =386.
Example 20 4-Fluoro-4-(3-methoxypyridin-2-yl)-N-[4-trifluoromethylphenyll piperidine- 1 -carboxamide The title compound was prepared from 2-bromo-3-methoxypyridine using the chemistry described for Description Example 1 and Example 1.
IH NMR δ (ppm) 400MHz (CDC13): 2.35-2.48 (4 H, m), 3.46-3.53 (2 H, m), 3.89 (3H, s) 3.98-4.03 (2 H, m), 6.57 (l H, s), 7.27 (2 H, d, J = 2.7Hz), 7.49-7.54 (4H, m), 8.17-8.2 (1 H, m). MSp m/z for MH+ =398.
Example 21 4-Fluoro-4-(3-methylpyridin-2-yl)-iV"-[4-trifluoromethylphenyll piperidine- 1-carbothioamide
The title compound was prepared using the procedure described in Example 10 with Description Example 3) and 4-trifluoromethylphenyl isothiocyanate.
IH NMR δ (ppm) 400MHz (CDC13): 2.14-2.21 (2 H, m), 2.47-2.65 (5 H, m), 3.60- 3.67 (2 H, m), 4.52-4.58 (2 H, m), 7.15 (l H, dd, J = 4.7, 7.4Hz), 7.23 (l H, s), 7.27
(2 H, d, J = 8.2Hz), 7.49 (l H, dd, J = 7.0, 0.8Hz), 7.60 (2 H, d, J = 8.2Hz), 8.35 (l
H, d, J = 4.7Hz). MSp m/z for MH+ =398. Example 22 Nr-cvano-4-fluoro-4-(3-methylpyridin-2-yl)-N:[4-tr-fluoromethyl phenyllpiperidine-1-carboximidamide Example 21 (39.7mg 0. lmmol), cyanamide (310mg, 7.4mmol) and silver acetate(l7mg, 0. lmmol) in acetonitrile (3ml) were heated in a pressurized microwave reactor at 140 °C for 10 minutes. The reaction was repeated on twice this scale and the reactions combined. The reactions were combined, evaporated and partitioned between dichloromethane (50ml) and water (50ml). The organics were washed with water (50ml), dried (Na2SO4) and evaporated. The desired compound (20mg) was obtained by column chromatography purification on silica using 25%- 100% ethyl acetate in isohexane as the eluant.
IH NMR δ (ppm) 400MHz (CDC13): 2.04-2.17 (2 H, m), 2.34-2.54 (5 H, m), 3.35- 3.43 (2 H, m), 3.90-3.95 (2 H, m), 7.10-7.16 (3 H, m), 7.18( IH s) 7.47 (IH d J=7Hz) 7.62 (2 H, d, J = 8.2Hz).8.34 (lH, d, J=4.7Hz) MSp m/z for MH+ =406.
Example 23 4-Fluoro-4-(3-methylpyridin-2-yl)-N-(l-phenylpiperidin-4-yl)-N-[4- trifluoromethylphenyl] piperidine- 1 -carboximidamide Example 21 (397mg, lmmol), l-phenylpiperidin-4-ylamine (l76mg, lmmol) and silver acetate (l67mg, lmmol) in acetonitrile (20ml) were heated at reflux overnight. The reaction mixture was evaporated, purified by column chromatography on silica using 2-10% methanol in dichloromethane as the eluant, followed by mass triggered HPLC purification using an acid based eluant. The free base was liberated using a strong cation exchange cartridge to give the desired compound (40mg). IH NMR δ (ppm) 400MHz (CDC13), 1.45-1.52 (2 H, m), 2.00-2.13 (4 H, m), 2.32- 2.52 (5 H, m), 2.74-2.80 (2 H, m), 3.25-3.31 (2 H, m), 3.37-3.46 (l H, m), 3.55-3.76 (4 H, m), 6.82-6.93 (5 H, m), 7.14 (l H, dd, J = 4.7, 7.4Hz), 7.23-7.27 (2 H, m), 7.48 - 7.52 (3 H, m), 8.37 (l H, d, J = 4.3Hz). MSp m/z for MH+ =540.
Example 24 4-Fluoro-4-phenyl-N-[4-trifluoromethylphenyl]piperidine-l- carboxamide
Using 4-fluoro-4-phenylpiperidine, 4-trifluoromethylphenylisocyanate and the procedure in Example 10 the title compound was obtained.
IH NMR δ (ppm) 400MHz (MeOD): 1.98-2.24 (4 H, m), 3.34-3.38 (2 H, m), 4.19-
4.24 (2 H, m), 7.28-7.32 (l H, m), 7.38 (2 H, m), 7.43 (2 H, m), 7.54 (2 H, d, J = 8.8Hz), 7.59 (2 H, d, J = 8.7Hz). MSp m/z for MH+ =367. Example 25 (+/-)-(svn)-4-fluoro-2-methyl-4-(3-methylpyridin-2-yl)-N-[4- trifluoromethylphenyl] piperidine- 1 -carboxamide Step !'• Zinc powder (48g, 734mmoles) was added iii a single portion to a stirred solution of 2-methyl-4-oxo-3,4-dihydro-2H-pyridine-l-carboxylic acid methyl ester (ll.38g, 67.3mmoles) (Cumins, D. L. and Akawar, R. S., Journal of Organic Chemistry, 1995, 60, 711-716 using methylmagnesium bromide as the Grignard reagent) in acetic acid (70ml) at room temperature. The reaction was then heated at reflux for 18 hours, cooled, the zinc filtered and washed with acetic acid. The resulting filtrate was evaporated in vacuo to give an orange oil. This was absorbed onto silica and purified by column chromatography on silica using 25% ethyl acetate in isohexane to give 2-methyl-4-oxopiperidine-l -carboxylic acid methyl ester as a clear oil (5.3g, 46% yield). IH NMR δ (ppm) 400MHz (DMSO): 1.10 (3 H, d, J = 7.0Hz), 2.15-2.28 (2 H, m), 2.43-2.48 (l H, m), 2.74 (l H, dd, J = 6.7, 14.9Hz), 3.34-3.38 (l H, m), 3.64 (3 H, s), 4.02-4.05 (1 H, m), 4.50-4.54 (l H, m). MSp m/z for MH+ = 172.
Step 2: Methyl 4-hydroxy-2-methyl-4-(3-methylpyridin-2-yl)piperidine-l- carboxylate was synthesized in the same manner as Description Example 1 using the product of Step 1 and 2-bromo-3-methylpyridine.
IH NMR δ (ppm) 400MHz (DMSO): 1.35 (3 H, d, J = 7.0Hz), 1.76-1.83 (2 H, m), 1.98-2.14 (2 H, m), 2.56 (3 H, s), 3.32-3.35 (l H, ), 3.60 (3 H, s), 3.85-3.91 (l H, m), 4.28-4.35 (l H, m), 5.28 (l H, s), 7.15-7.18 (l H, m), 7.52-7.54 (l H, m), 8.29 (l H, dd, J = 6, 1.3 Hz). MSp m/z for MH+ = 265.
Step 3: 47% hydrogen bromide in acetic acid (3ml, excess) was added dropwise to a stirred solution of the product of Step 2 (361mg, 1.4mmoles) in acetic acid (lml) and stirred at room temperature for 48 hours. The reaction was concentrated in vacuo to give a pale brown solid. This was then reacted with 4- trifluoromethylphenylisocyanate using the same procedure as for Example 1 to give crude material which was purified by mass- triggered HPLC using an acid based eluant , and strong cation exchange cartridge to give (+/-)-(syn)-4-hydroxy- 2-methyl-4-(3-methylpyridin-2-yl)-N-[4-trifluoromethylphenyllpiperidine-l- carboxamide free base as a white solid (256mg, 46%). IH NMR δ (ppm) 400MHz (DMSO): 1.42 (3 H, d, J = 6.7Hz), 1.84-1.87 (2 H, m), 2.09-2.16 (1 H, m), 2.20-2.34 (l H, m), 2.58 (3 H, s), 3.38-3.46 (l H, m), 3.96-4.00 (1 H, m), 4.50-4.53 (l H, m), 5.31 (l H, s), 7.16-7.19 (l H, m), 7.53-7.57 (3 H, m), 7.69 (2 H, d, J = 9.6Hz), 8.31 (l H, dd, J = 3.9, 0.8Hz), 8.81 (l H, m). MSp m/z for MH+ = 394.
Step 4: To a suspension of the product of Step 3 (221mg, 0.56mmol) in dichloroethane (lOml) at -78°C diethylaminosulphur trifluoride (l44μl, 1.18mmol) was added dropwise. Workup was analogous to Description Example 2, to give crude product which was purified via column chromatography on silica using 10-20% ethyl acetate in isohexane to give the desired product (8mg, 4%). IH NMR δ (ppm) 500MHz (MeOD): 1.15 (3 H, d, J = 6.6Hz), 2.21-2.49 (3 H, m), 2.50 (2 H, s), 2.51 (3 H, d, J = 4.8Hz), 2.58-2.67 (l H, m), 3.53-3.59 (l H, m), 4.06- 4.11 (1 H, m), 4.38-4.45 (l H, m), 7.24 (l H, dd, J = 4.7, 7.6Hz), 7.54 (2 H, d, J = 8.7Hz), 7.60 (2 H, d, J = 8.8Hz), 8.36 (l H, d, J = 4.6Hz). MSp m/z for MH+ = 396.
Example 26 4-(Fluoromethyl)-4-pyridin-2-yl-N-[4-trifluoromethylphenyl] piperidine- 1-carboxamide Step 1: Sodium hydride (60% in mineral oil, 2.04g, δlmmol) was added portion wise over 8 minutes to a stirring solution of 2-pyridineacetonitrile (l.8ml,
17mmol) and N-(tert-butyloxycarbonyl)bis(2-chloroethyl)amine in anhydrous DMF (50ml) at 0°C. The reaction was then heated at 60°C for 5 % hours. The reaction was cooled and extracted into ethyl acetate (4 x 150ml), and washed with water (3 x 200ml). The organic layer was then dried over anhydrous MgSO4, filtered and evaporated in vacuo to give a red/black oil. This was absorbed onto silica and purified by column chromatography using 20% ethyl acetate in isohexane to give tert-butyl 4-cyano-4-pyridin-2-ylpiperidine-l-carboxylate as an orange solid (2.13g, 44%). IH NMR δ (ppm) 360MHz (CDC13): 1.48 (9 H, s), 2.04-2.08 (2 H, m), 2.17-2.25 (2 H, m), 3.15-3.28 (2 H, m), 4.20-4.35 (2 H, m), 7.25-7.29 (l H, m), 7.61 (l H, d, J = 8Hz), 7.73-7.78 (l H, ), 8.61 (l H, dd, J = 0.7, 3.9Hz). MSp m z for MH+ = 287 (■ 56). Step 2 HC1 gas was bubbled through a solution of the product of Step 1 (lg, 3.5mmol) in anhydrous methanol (20ml) for 10 minutes at 0°C. This was warmed to room temperature and stirred for 48 hours, then evaporated in vacuo. The resulting solid (l.03g, 3.5mmol) was suspended in anhydrous dichloroethane (25ml). To the stirring suspension at 0°C triethylamine (l.lml, 7.7mmol), benzaldehyde (400μl, 3.85mmol) and 3A molecular sieves (5g) were added and allowed to stirred at room temperature for 15 minutes before sodium cyanoborohydride (242mg, 3.85mmol) was added in a single portion and the solution stirred at room temperature for 18 hours. The solvent was then evaporated in vacuo, to the residue water (50mD was added and extracted into ethyl acetate (2 x 50ml). The organic layer was dried over anhydrous MgSO4, filtered and evaporated in vacuo to give an orange oil. This was purified by column chromatography on silica using 0-5% methanol in dichloromethane as eluant. This gave methyl l-benzyl-4-pyridin-2-ylpiperidine-4-carboxylate as an orange oil (820mg, 76%).
IH NMR δ (ppm) 360MHz (CDC13): 2.10-2.1 (2 H, m), 2.23-2.29 (2 H, m), 2.49- 2.54 (2 H, m), 2.74-2.77 (2 H, m), 3.47 (2 H, s), 3.69 (3 H, s), 7.16 (l H, dd, J = 5.1, 7.2Hz), 7.28-7.34 (6 H, m), 7.64 (l H, td, J = 7.7, 1.7Hz), 8.56 (l H, dd, J = 0.7, 3.9Hz).MSp m/z for MH+ = 311.
Step 3: Lithium aluminium hydride (lM in tetrahydrofuran, lml, lmmol) was added to a stirred solution of the product of Step 2 (320mg, lmmol) in anhydrous THF (3ml) at -30°C and stirred at this temperature for 1 hour. Water (2ml) was added then extracted into ethyl acetate (2 x 5ml) organic layers combined, dried over anhydrous MgSO4, filtered, filtrate evaporated in vacuo to give (l-benzyl-4- pyridin-2-ylpiperidin-4-yl)methanol as an orange oil which solidified on standing (263mg, 93%).
IH NMR δ (ppm) (CDC13): 1.89-1.94 (2 H, m), 2.14-2.21 (2 H, m), 2.43-2.56 (4 H, m), 3.51 (2 H, s), 3.80 (2 H, s), 7.14-7.17 (l H, m), 7.19-7.34 (5 H, m), 7.37 (l H, d, J = 8.1Hz), 7.66-7.71 (l H, m), 8.52 (l H, dd, J = 0.7, 3.9Hz). MSp m/z for MH+ = 283.
Step 4: A slurry of 10% palladium on carbon (84mg) was added to a solution of the product of Step 3 (l24mg, 0.44mmol) in ethanol (lOml). This was hydrogenated at room temperature under atmospheric pressure for 72 hours. The catalyst was filtered, washed with ethanol, and the filtrate concentrated in vacuo. The resulting amine (85mg, 0.44mmol) was dissolved in dichloromethane (lOml), to the stirring solution drtert-butyldicarbonate (95mg, 0.44mmol) added and stirred at room temperature for 2 hours. The reaction was evaporated in vacuo, extracted into ethyl acetate and washed with water, then the organic layer dried over MgSO4, filtered and evaporated to give tert-butyl 4-_ιydroxymethyl-4- pyridin-2-ylpiperidine-l-carboxylate as an off-white solid (l20mg, 93%). IH NMR δ (ppm) 400MHz (CDC13): 1.46 (9 H, s), 1.80-1.86 (2 H, m), 2.07-2.14 (2 H, m), 3.43-3.49 (4 H, m), 3.80 (2 H, bs), 3.94 (l H, bs), 7.16-7.21 (l H, m), 7.33 (l H, d, J = 8.2Hz), 7.68-7.73 (l H, m), 8.53-8.57 (l H, m). MSp m/z for MH+ = 237 (-56).
Step 5: Diethylaminosulphur trifluoride (76μl, 0.62mmol) was added to a stirring solution of the product of Step 4 (I20mg, 0.41mmol) in anhydrous ethyl acetate (3ml) at — 78°C. The reaction was allowed to warm to RT overnight. The solution was evaporated and to the resulting oil tetrabutylammonium fluoride (1M solution in tetrahydrofuran, 820μl 0.82mmol) added and refluxed for 2 hours. The reaction was cooled to RT water (3ml) added and the aqueous layer was • extracted with ethyl acetate (3 x 5ml). The combined organics were dried over MgSO4, filtered and the filtrate evaporated in vacuo. The resulting oil was stirred in trifluoroacetic acid (lml) for 1 hour, the solvent then evaporated and the residue dissolved in dichloromethane. To this stirring solution triethylamine (l23μl, 0.90mmol), and 4-trifluoromethylphenyHsocyanate (59μl, 0.41mmol) were added and the solution stirred at room temperature for 18 hours. The reaction was evaporated, water (5ml) added and extracted with ethyl acetate (3 x 5ml). The combined organics were evaporated to give an oily orange compound. This was washed with dichloromethane and purified on a silica prep plate using 5% methanol in dichloromethane with 0.1% ammonia as the eluant. This gave the desired compound as a white solid (l.8mg, 1%). IH NMR δ (ppm) 500MHz (MeOD): 1.89-1.94 (2 H, m), 2.48-2.51 (2 H, m), 3.08- 3.15 (2 H, m), 3.92-3.97 (2 H, m), 4.45 (2 H, d, J = 48Hz), 7.28-7.30 (l H, m), 7.51- 7.67 (5 H, m), 7.80-7.84 (l H, m), 8.60-8.61 (l H, m).MSp m/z for MH+ = 382. Examples 27 and 28 <S,W2- ai_c. _4--t7'-3-fluoro-3-pyridin-2-yl-N [4-trifluoromethyl phenyl]-8-azabicvclo[3.2.l]octane-8-carboxamide & 3-fluoro -3-pyridin-2-yl-N- [4-trifluoromethylphenyl] -8-azabicvclo [3.2.l]octane-8-carboxamide Step l: 2-Lithiopyridine was added to tert-butoxycarbonyltropinone according to the procedure in Description Example 1 to give 3-hydroxy-3-pyridin-2-yl-8- azabicyclo[3.2.l]octane-8-carboxylic acid tertrhutyl ester. Without complete purification, the product was treated according to the procedure in Description Example 2 to give 3-fluoro-3-pyridin-2-yl-8-azabicyclo[3.2.l]octane-8-carboxylic acid ferrtiutyl ester as a 1.2:1 mixture of syn-anti isomers. Syn- IH NMR δ
(ppm) 500MHz(CDCl3): 1.50 (9 H, s), 1.88-2.19 (4 H, m), 2.33 (2 H, m), 2.68 (2 H, m), 4.47 (2 H, m), 7.15 (l H, m), 7.49 (l H, m), 7.67 (l H, m), 8.52 (l H, m). MSp m z for MH+ =307. Anti- lH NMR δ (ppm) 500MHz(CDCl3): 1.51 (9 H, s), 1.93 (2 H, m), 2.33 (2 H, m), 2.59 (4 H, m), 4.47 (2 H, m), 7.22 (l H, m), 7.62 (l H, m), 7.71 (1 H, m), 8.56 (l H, m). MSp m/z for MH+ =307.
Step 2a: The major isomer of the product of Step 1 was treated according to the procedure in Example 1 to give the title compound (Example 27). IH NMR δ (ppm) 700MHz(CDCl3): 2.07 (2 H, d, J 16.8 Hz), 2.14 (2 H, m), 2.33 (2 H, dd, J 14.0, 6.3 Hz), 2.75 (2 H, m), 4.51 (2 H, brs), 6.58 (l H, s), 7.21 (l H, m), 7.50 (l H, m), 7.56 (4 H, m), 7.73 (l H, m), 8.53 (l H, m). MSp m/z for MH+ =394.
Step 2b: The minor isomer of the product of Step 1 was treated according to the procedure in Example 1 to give the title compound (Example 28). IH NMR δ (ppm) 700MHz(CDCl3): 1.80 (2 H, dd, J 14.0, 6.3 Hz), 2.07 (2 H, dd, J 7.0, 3.5 Hz), 2.60 (4 H, m), 4.48 (2 H, brs), 6.56 (l H, s), 7.25 (l H, m), 7.55 (2 H, d, J 9.1 Hz), 7.57 (2H, d, J 9.1 Hz), 7.61 (l H, m), 7.74 (l H, m), 8.58 (l H, m). MSp m/z for MH+ =394.
Example 29 4-Fluoro-4-pyrimidin-2-yl-N-[4-trifluoromethylphenyl]piperidine-l- carboxamide
Step !'■ 4-Hydroxy-4-pyrimidin-2-ylpiperidine-l-carboxylic acid fort-butyl ester was prepared according to WO-A-9903847 and then treated according to the procedure in Description Example 2 to give 4-fluoro-4-pyrimidin-2-ylpiperidine-l- carboxylic acid fert-butyl ester. IH NMR δ (ppm) 400MHz(CDCl3): 1.48 (9 H, s), 2.08-2.34 (4 H, m), 3.27 (2 H, m), 4.08 (2 H, m), 7.27 (l H, t, J 4.7 Hz), 8.79 (2 H, d, J 4.7 Hz).
Step 2: The product of Step 1 was treated according to the procedure in Example 1 to give the title compound. IH NMR δ (ppm) 500MHz(CDCl3): 2.25-2.44 (4 H, m), 3.49 (2 H, m), 4.07 (2 H, m), 6.56 (1 H, s), 7.29 (l H, t, J 4.8 Hz), 7.49 (2 H, d, J 8.7), 7.55 (2 H, d, J 8.7), 8.81 (2 H, d, J 4.8 Hz). MSp m/z for MH+ =369.
Example 30 4-Fluoro-4-(3-phenylpropyl)-N-[4-trifluoromethylphenyllpiperidine- 1 -carboxamide The title compound was prepared using a procedure analogous to that in Example 7 using 4-fluoro-4-(3-phenylpropyl)piperidine hydrochloride as the amine.
IH NMR δ (ppm) 400MHz(DMSO): 1.43-1.82 (8H, m), 2.53-2.63 (2 H, m), 3.03- 3.10 (2 H, m), 3.92-3.98 (2 H, mz), 7.14-7.23 (3 H, m), 7.26-7.30 (2 H, m), 7.57 (2H, d J=8.6Hz), 7.68 (2H, d J=8.6Hz), 8.91 (l H, s). MSp m/z for MH+ =409.
Example 31 2- [4-Fluoro-4-(3-methylpyridin-2-yl)piperidin- 1-yl] -6- trifluoromethyl- lH-benzimidazole Description Example 3 (87.2mg, 0.46mmol) was treated with ethanol (lml) and 2- chloro-5-(trifluoromethyl)-lH-benzimidazole (lOOmg, 0.46mmol) (WO-A-021471) and heated in a pressurized microwave vessel at 160°C for 10 minutes. After evaporation, the compound was purified by column chromatography using 2-5%methanol in dichloromethane as the eluant to give 2- [4-hydroxy-4-(3-methylpyridin-2-yl)piperidin- 1-yl] -6 -trifluoromethyl- 1H- benzimidazole (l8mg) (MSp m/z for MH+ =377). This was converted to the title compound using the procedure outlined in Description Example 2.
IH NMR δ (ppm) 400 MHz (DMSO): 1.9-2.05 (2H, m), 2.508-2.27(2 H, m), 2.32 - 2.34(3 H, m), 3.20-3.32 (2 H, m), 3.96-4.03 (2H, m), 7.04-7.21 (3 H, m), 7.23-7.35 (1 H, m), 7.48 (lH, d J=6.7Hz), 8.17 (lH, d J=4.3Hz), 11.67-11.72 (l H, m). MSp m/z for MH+ =379. Example 32 2-(4-Fluoi -4-pyridin-2-ylpiperidin-l-yl)-6-(trifluoromethyl)-lJ_"- benzimidazole The title compound was prepared using a procedure analogous to that in 5 Example 31 from Description Example 4. IH NMR δ (ppm) (CDC13):, 2.02-2.07 (2 H, m), 2.41-2.59 (2 H, m), 3.56-3.61 (2 H, m), 4.10-4.13 (2 H, m), 7.22-7.59 (6 H, m), (7.73-7.79 (l H, m), 8.52-8.53 (l H, m). MSp m/z for MH+ =365.
10 Example 33 4-Fluoro-N- [4-trifluoromethylphenyl] -4- [3-trifluoromethylpyridin-2- yll piperidine- 1 -carboxamide 2-bromo-3-trifluoromethylpyridine (l.l3g,5mmol) and l-butoxycarbonyl-4- piperidone (lg, δmmol) in THF(20ml) was cooled to -78°C and tert-butyllithium (4.4ml, 1.7M in pentane, 7. δmmol) was added dropwise to this solution. After lδ stirring at this temperature for 30 minutes, the reaction mixture was allowed to warm to room temperature over two hours. Water (δOml) was added and the aqueous was extracted using ethyl acetate (3 x 60ml). The combined organics were dried over sodium sulphate and evaporated. Column chromatography on silica using 10-20% ethyl acetate in isohexane as eluant gave fort-butyl 4-
20 hydroxy-4-(3-trifluoromethylpyridin-2-yl)piperidine-l-carboxylate contaminated with l-butoxycarbonyl-4-piperidone (6δ0mg). This mixture was converted to the desired compound using the chemistry described in Description Example 2 and Example 1. IH NMR δ (ppm) 400MHz (CDC13 ) 2.13-2.06 (2 H, m), 2.60-2.42 (2 H, m), 3.46-
25 3.40 (2 H, m), 4.11 (2 H, dd, J = 4.8, 13.4 Hz), 6.61 (l H, s), 7.42-7.36 (l H, m), 7.48-7.57 (4 H,m), 8.11 (l H, d, J = 8.0 Hz), 8.70 (l H, d, J = 4.6 Hz). MSp m/z for MH+ =436.
Examples 34 to 39 were made using the procedure shown in Example 10 using 30 Description Example 3 and 4-tolyl isocyanate, 4-ethylphenyl isocyanate, 4- chlorophenyl isocyanate, 4-trifluoromethoxy isocyanate, 4-cyanophenyl isocyanate and 4-dimethylammophenyl isocyanate respectively. Example 34 4-Fluoro-N-(4-methylphenyl)-4-(3-methylpyridin-2-yl)piperidine-l- carboxamide IH NMR δ (ppm) 400MHz(CDC13): 2.11-2.17 (2 H, m), 2.30 (3 H, s), 2.50 (5 H, m), 3.38-3.44 (2 H, m), 4.03-4.15 (2 H, m), 6.34 (l H, s), 7.10-7.14 (3 H, m), 7.23-7.26 5 (2 H, m), 7.48 (l H, d, J = 8 Hz), 8.35 (l H, d, J = 4.6 Hz). MSp m/z for MH+ =328.
Example 35 N-(4-ethylphenyl)-4-fluoro-4-(3-methylpyridin-2-yl)piperidine-l- carboxamide 10 IH NMR δ (ppm) 360MHz (CDC13): 1.21 (3 H, t, J = 7.6 Hz), 2.11-2.17 (2 H, m), 2.34-2.52 (5 H, m),2.6 (2H, q, J=7.6Hz) 3.37-3.45 (2 H, m), 4.02-4.08 (2 H, m), 6.36 (1 H, s), 7.12-7.14 (3 H, m),7.25-7.28 (2 H, m) 7.48 (l H, d, J = 7.0 Hz), 8.36 (1 H, d, J = 4.6 Hz). MSp m/z for MH+ =342.
lδ Example 36 N-(4-chlorophenyl)-4-fluoro-4-(3-methylpyridin-2-yl)piperidine-l- carboxamide IH NMR δ (ppm) 360MHz (CDC13): 2.12-2.18 (2 H, m), 2.34-2.δ2 (δ H, m), 3.38- 3.46 (2 H, m), 4.04 (2 H, d, J = 13.4 Hz), 6.42 (l H, s), 7.14 (l H, dd, J = 4.7, 7.7 Hz), 7.24-7.28 (2 H, m), 7.30-7.34 (2 H, m) 7.49 (l H, d, J = 7.7 Hz), 8.3δ (l H, d, J
20 = 4.7 Hz). ). MSp m/z for MH+ =348.
Example 37 4-Fluoro-4-(3-methylpyridin-2-yl)-N-[4-trifluoromethoxyphenyl1 piperidine- 1 -carboxamide IH NMR δ (ppm) 360 MHz (CDC13): 2.12-2.20 (2 H, m), 2.34-2.63 (δ H, m), 3.39- 2δ 3.47 (2 H, m), 4.01-4.09 (2 H, m), 6.46 (l H, s), 7.12-7.18 (3 H, m), 7.37-7.41 (2 H, m), 7.49 (1 H, d, J = 7.7 Hz), 8.36 (l H, d, J = 4.8 Hz). MSp m/z for MH+ =398.
Example 38 N-(4-cvanophenyl)-4-fluoro-4-(3-methylpyridin-2-yl)piperidine-l- carboxamide 30 IH NMR δ (ppm)360 MHz (CDC13): 2.11-2.22 (2 H, m), 2.35-2.63 (5 H, m), 3.41- 3.49 (2 H, m), 4.02-4.11 (2 H, m), 6.68 (l H, s), 7.15 (l H, dd, J = 4.7, 7.7 Hz), 7.49- 7.59 (5 H, m), 8.3δ (l H, d, J = 4.6 Hz). MSp m/z for MH+ =339. Example 39 N- [4-dimethylaminophenyll -4-fluoro-4-(3-methylpyridin-2-yl) piperidine- 1-carboxamide IH NMR δ (ppm) 400MHz (DMSO): 2.01-2.08 (2 H, t, J = 12.1 Hz), 2.16-2.33 (2 H, m), 2.49 (3 H, d J=5.4Hz), 2.87 (6 H, s), 3.12-3.25 (2 H, m), 4.06-4.16 (2 H, m), 6.74 (2 H, s), 7.27-7.31 (5 H, m) , 7.66 (l H, d, J = 6.9 Hz), 8.33-8.41 (2 H, m). MSp m/z for MH+ =357.

Claims

A compound of formula (I):
Figure imgf000037_0001
(I)
wherein: A1 is phenyl, a six-membered aromatic heterocycle containing one, two or three nitrogen atoms, or a five-membered aromatic heterocycle containing up to four heteroatoms chosen from O, N and S, at most one heteroatom being O or S. A1 is unsubstituted or substituted by one, two or three substituents independently chosen from halogen, Ci-ealkyl, C2-βalkenyl, C2-6alkynyl, haloCi-ealkyl, Ci-βalkoxy, haloCi-ealkoxy, hydroxy, cyano, nitro and amino; A2 is phenyl, a six-membered aromatic heterocycle containing one, two or three nitrogen atoms, or a five-membered aromatic heterocycle containing up to four heteroatoms chosen from O, N and S, at most one heteroatom being O or S; A2 is unsubstituted or substituted by one, two or three groups independently chosen from halogen, cyano, nitro, amino, Cι-6alkylamino, di(Cι-6alkyl)amino, Ci-βalkyl C2-6alkenyl, C2-6alkynyl, haloCi-ealkyl, hydroxy, Ci-ealkoxy, haloCi-ealkyl, thiol, SF5, phenylCi-βalkyl and phenyl; L is a bond or Ci-βalkylene; R1 and R2 independently chosen from hydrogen and Ci-βalkyl; or R1 and R2 may, together, form a methylene or ethylene bridge; W is halogen, Ci-βalkyl, haloCi-ealkyl, Ci-ealkoxy or haloCi-ealkoxy; X is O, S or NR3 where R3 is hydrogen, hydroxy, Ci-βalkoxy, Ci-ealkyl, cyano, C3-ecycloalkyl, a six-membered saturated heterocycle containing one or two heteroatoms independently chosen from O, N and S, and R3 is, if possible, optionally substituted by Ci-ealkyl, Ci-βalkoxy, haloCi-ealkyl, haloCi-ealkoxy, halogen, amino, nitro, hydroxy, phenyl, a six-membered aromatic heterocycle containing up to three nitrogen atoms or a five-membered aromatic heterocycle containing up to four heteroatoms chosen from O, N and S, at most one heteroatom being O or S; or X, together with the atom to which it is attached, and Y, form an unsaturated five-membered ring together with A2; Y is a bond, Cι-4alkylene, NH or NH(CH2)ι-3Ϊ or a pharmaceutically acceptable salt thereof. 2. A compound selected from:
4-fluoro-4-(3-methylpyridin-2-yl)-N-[4-tr_fluoromethylphenyl]piperidine-l- carboxamide;
4-fluoro-4(pyridin-2-yl)N[4-trifluoromethylphenyl]piperidine-l-carboxamide;
4-fluoro-4(pyridine-2-yl)N-[4-trifluoromethylbenzyl]piperidine-l-carboxamide; 2-{4-fluoro-l-[4-trifluoromethylbenzoyl]piperidin-4-yl}pyridine;
2-(4-fluoro-l-{[4-trifluoromethylphenyl]acetyl}piperidin-4-yl)pyridine;
2 - (4-fluoro- 1 - {3 - [4-trifluoromethylphenyl] prop anoyl}piperidin- 4-yl)pyridine
4-fluoro-4-(l-methyl-lH-imidazol-2-yl)-N-[4-trifluoromethylphenyl]piperidine-l- carboxamide; 4-methoxy-4-pyridin-2-yl-N^ [4-trifluoromethylphenyl] piperidine- 1 -carboxamide;
4-methoxy-4-pyridin-2-yl-N-[4-trifluoromethylbenzyl]piperidine-l-carboxamide;
4-fluoro-N-(4-isopropylphenyl)-4-(3-methylpyridin-2-yl)piperidine-l-carboxamide;
4-fluoro-4-(3-methylpyridin-2-yl)-N{4-[l,2,2,2-tetrafluoro-l-trifluoiOmethylethyl] phenyl}piperidine-l_carboxamide; _V(4- _rfer^butylphenyl)-4-fluoro-4-(3-methylpyridin-2-yl)piperidine- 1- carboxamide;
4-fluoro-4-(3-methylpyridin-2-yl)-N-[4-(pentafluoro-λ6-sulfanyl)phenyl]piperidine-
1 -carboxamide;
N-(4-Butylphenyl)-4-fluoro-4-(3-methylpyridin-2-yl)piperidine-l-carboxamide; Ν-(4-Benzylphenyl)-4-fluoro-4-(3-methylpyridin-2-yl)piperidine-l-carboxamide; N-biphenyl-4-yl-4-fluoro-4-(3-methylpyridin-2-yl)piperidine-l-carboxamide; 4-fluoro-4-(3-methylpyridin-2-yl)-N-[δ-trifluoromethylpyridin-2-yl]piperidine-l- carboxamide; 4-(3-chloropyridin-2-yl)-4-fluoro-N-[4-trifluoromethylphenyl]piperidine-l- 5 carboxamide 4-fluoro-4-(3-fluoropyridin-2-yl)-N-[4-trifluoromethylphenyl]piperidine-l- carboxamide; 4-fluoro-4-(3-methoxypyridin-2-yl)-N-[4-trifluoromethylphenyl]piperidine-l- carboxamide; 10 4-fluoro-4-(3-methylpyridin-2-yl)-N-[4-trifluoromethylphenyl]piperidine-l- carbothioamide; Nr-cyano-4-fluoro-4-(3-methylpyridin-2-yl)-A^[4-trifluoromethylphenyl]piperidine- 1-carboximidamide; 4-fluoro-4-(3-methylpyridin-2-yl)-N-(l-phenylpiperidin-4-yU-N-[4- lδ trifluoromethylphenyl] piperidine- 1-carboximidamide; 4-fluoro-4-phenyl-N-[4-tri_luoromethylphenyl]piperidine-l-carboxamide; (+/-)-(syn)-4-fluoro-2-methyl-4-(3-methylpyridin-2-yl)-Ν-[4- trifluoromethylphenyl] piperidine- 1 -carboxamide; 4- (fluoromethyl) - 4-pyridin- 2 -yl- N- [4- trifluoromethylphenyl] pip eridine- 1 - 20 carboxamide; syn- and _ϊ_ tϊ-3-fluoro-3-pyridin-2-yl-N-[4-trifluoromethylphenyl]-8- azabicyclo[3.2.l]octane-8-carboxamide & 3-fluoro-3-pyridin-2-yl-N-[4- trifluoromethylphenyl] - 8-azabicyclo [3.2.1] octane- 8-carboxamide; 4-fluoro-4-pyrimidin-2-yl-N[4-trifluoromethylphenyl]piperidine-l-carboxamide; 2δ 4-fluoro-4-(3-phenylpropyl)-N-[4-trifluoromethylphenyl]piperidine-l-carboxamide; 2- [4-fluoro-4- (3 - methylpyridin- 2-yl)piperidin- 1 -yl] - 6 -trifluoromethyl- 1 H~ benzimidazole; 2-(4-fluoro-4-pyridin-2-ylpiperidin-l-yl)-6-(trifluoromethyl)-lHr-benzimidazole; 4-fluoro-Ν-[4-trifluoromethylphenyl]-4-[3-trifluoromethylpyridin-2-yl]piperidine- 30 1-carboxamide; 4-fluoro-N-(4-methylphenyl)-4-(3-methylpyridin-2-yl)piperidine-l-carboxamide; N-(4-ethylphenyl)-4-fluoro-4-(3-methylpyridin-2-yl)piperidine- 1-carboxamide; N-(4-chlorophenyl)-4-fluoro-4-(3-methylpyridin-2-yl)piperidine-l-carboxamide; 4-fluoro-4-(3-methylpyridin-2-yl)-N-[4-trifluoromethoxyphenyl]piperidine-l- carboxamide;
N-(4-cyanophenyl)-4-fluoro-4-(3-methylpyrio_ϋα-2-yl)piperidine-l-carboxamide; N-[4-(hmethylam_nophenyl]-4-fluoro-4-(3-methylpyriα^-2-yl)piperidine-l- carboxamide; and pharmaceutically acceptable salts thereof.
3. A pharmaceutical composition comprising one or more compounds of claim 1 or 2, or pharmaceutically acceptable salts thereof in association with a pharmaceutically acceptable carrier or excipient.
4. A compound of claim 1 or 2, or a pharmaceutically acceptable salt thereof, for use in treatment of the human or animal body.
5. The use of a compound of claim 1 or 2, or a pharmaceutically acceptable salt thereof for use in the manufacture of a medicament for the treatment or prevention of physiological disorders that may be ameliorated by modulating VRl activity.
6. The use of a compound of claim 1 or 2, or a pharmaceutically acceptable salt thereof for use in the manufacture of a medicament for the treatment or prevention of a disease or condition in which pain and/or inflammation predominates.
7. The process for the preparation of a compound of claim 1, which comprises:
(A) for compounds wherein Y is NH or NH(CH2)ι-3, reacting a compound of formula (II) with a compound of formula (III): Ή?
Figure imgf000041_0001
(ID (III)
wherein X1 is O or S, P is H or a Ci-βalkoxycarbonyl group such as tert- butoxycarbonyl and A1, A2, L, R1, R2 and W are as defined in claim l;
(B) for compounds wherein Y is a bond or Cι-4alkylene, reacting a compound of formula (II) with a compound of formula (IV):
Figure imgf000041_0002
(IV)
wherein both *s are O or S, Y is a bond or Cι-4alkylene and A2 is as defined in claim L" or
(C) for compounds wherein X, together with the atom to which it is attached, and Y, form an unsaturated five membered ring together with A2, reacting a compound of formula (II) with a compound of formula (V):
Figure imgf000041_0003
(v)
wherein X, together with the atom to which it is attached and Y, form an unsaturated five membered ring together with A2.
8. A method for the treatment or prevention of physiological disorders that may be ameliorated by modulating VRl activity, which method comprises administration to a patient in need thereof of an effective amount of a compound of claim 1 or a composition comprising a compound of claim 1.
9. A method for the treatment or prevention of a disease or condition in which pain and/or inflammation predominates, which method comprises administration to a patient in need thereof of an effective amount of a compound of claim 1, or a composition comprising a compound of claim 1.
PCT/GB2004/004538 2003-10-29 2004-10-27 E-fluoro-4-(pyridin-2-yl)-piperidine-1-carboxamide derivatives and related compounds which modulate the function of the vanilloid-1 receptor (vr1) for the treatment of pain WO2005051390A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP04769034A EP1682141A1 (en) 2003-10-29 2004-10-27 4-fluoro-4-(pyridin-2-yl)-piperidine-1-carboxamide derivatives and related compounds which modulate the function of the vanilloid-1 receptor (vr1) for the treatment of pain
AU2004292382A AU2004292382A1 (en) 2003-10-29 2004-10-27 E-fluoro-4-(pyridin-2-yl)-piperidine-1-carboxamide derivatives and related compounds which modulate the function of the vanilloid-1 receptor (VR1) for the treatment of pain
US10/577,585 US20070135423A1 (en) 2003-10-29 2004-10-27 E-fluoro-4-(pyridin-2-yl)-piperidine-1-carboxamide derivatives and related compounds which modulate the function of the vanilloid-1 receptor (vr1) for the treatment of pain
JP2006537408A JP2007509915A (en) 2003-10-29 2004-10-27 4-Fluoro-4- (pyridin-2-yl) piperidine-1-carboxamide derivatives and related compounds that modulate the function of vanilloid 1 receptor (VR1) for the treatment of pain

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0325287.1A GB0325287D0 (en) 2003-10-29 2003-10-29 Therapeutic agents
GB0325287.1 2003-10-29

Publications (1)

Publication Number Publication Date
WO2005051390A1 true WO2005051390A1 (en) 2005-06-09

Family

ID=29725601

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2004/004538 WO2005051390A1 (en) 2003-10-29 2004-10-27 E-fluoro-4-(pyridin-2-yl)-piperidine-1-carboxamide derivatives and related compounds which modulate the function of the vanilloid-1 receptor (vr1) for the treatment of pain

Country Status (7)

Country Link
US (1) US20070135423A1 (en)
EP (1) EP1682141A1 (en)
JP (1) JP2007509915A (en)
CN (1) CN1874775A (en)
AU (1) AU2004292382A1 (en)
GB (1) GB0325287D0 (en)
WO (1) WO2005051390A1 (en)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7126026B2 (en) 2003-11-13 2006-10-24 Sanofi-Aventis Deutschland Gmbh Process for preparing 4-pentafluorosulfanylbenzoylguanidines
US7317124B2 (en) 2003-11-13 2008-01-08 Sanofi-Aventis Deutschland Gmbh Ortho-substituted pentafluorosulfanylbenzenes, process for their preparation and their use as valuable synthetic intermediates
WO2008010061A2 (en) * 2006-07-17 2008-01-24 Glenmark Pharmaceuticals S.A. 3-azabicyclo [3.1.0] hexane vanilloid receptor ligands, pharmaceutical compositions containing them, and processes for their preparation
US7622611B2 (en) 2003-11-13 2009-11-24 Sanofi-Aventis Deutschland Gmbh Pentafluorosulfanylbenzoylguanidines, process for their preparation, use as a medicament or diagnostic aid, and medicament comprising same
EP2259680A1 (en) * 2008-03-04 2010-12-15 Merck Sharp & Dohme Corp. Soluble epoxide hydrolase inhibitors, compositions containing such compounds and methods of treatment
US7994167B2 (en) * 2005-05-20 2011-08-09 Gruenenthal Gmbh Pentafluorosulphanyl-substituted compound and its use for producing medicaments
US8044052B2 (en) 2006-10-18 2011-10-25 Pfizer Inc. Biaryl ether urea compounds
WO2011143365A1 (en) * 2010-05-13 2011-11-17 Amgen Inc. Nitrogen heterocyclic compounds useful as pde10 inhibitors
EP2484664A1 (en) * 2008-05-07 2012-08-08 Dainippon Sumitomo Pharma Co., Ltd. Cyclic amine-1-carboxylic acid ester derivative and pharmaceutical composition containing the same
US8338603B2 (en) 2007-10-24 2012-12-25 Abbvie Inc. TRPV1 antagonists
US8455520B2 (en) 2007-07-17 2013-06-04 Merck Sharp & Dohme Corp. Soluble epoxide hydrolase inhibitors, compositions containing such compounds and methods of treatment
US8557872B2 (en) 2008-01-28 2013-10-15 Amorepacific Corporation Compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same
US8691855B2 (en) 2008-07-02 2014-04-08 Amorepacific Corporation Compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist and pharmaceutical compositions containing the same

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080153845A1 (en) * 2006-10-27 2008-06-26 Redpoint Bio Corporation Trpv1 antagonists and uses thereof
PT2142529E (en) 2007-04-27 2014-03-20 Purdue Pharma Lp Trpv1 antagonists and uses thereof
WO2010064597A1 (en) * 2008-12-01 2010-06-10 武田薬品工業株式会社 Piperidine derivative
WO2011021645A1 (en) * 2009-08-19 2011-02-24 大日本住友製薬株式会社 Bicyclic urea derivative or pharmacologically permitted salt thereof
JP2013028536A (en) * 2009-11-11 2013-02-07 Dainippon Sumitomo Pharma Co Ltd Cyclic amine-1-carboxylic acid ester derivative and pharmaceutical composition containing the same
WO2012061505A1 (en) 2010-11-03 2012-05-10 University Of Hawaii Methods and compositions for prevention and treatment of cardiac hypertrophy
TW202218659A (en) * 2020-09-07 2022-05-16 日商大日本住友製藥股份有限公司 Phenol derivative

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000064884A1 (en) * 1999-04-26 2000-11-02 Novo Nordisk A/S Piperidyl-imidazole derivatives, their preparations and therapeutic uses
WO2002008221A2 (en) * 2000-07-20 2002-01-31 Neurogen Corporation Capsaicin receptor ligands

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000064884A1 (en) * 1999-04-26 2000-11-02 Novo Nordisk A/S Piperidyl-imidazole derivatives, their preparations and therapeutic uses
WO2002008221A2 (en) * 2000-07-20 2002-01-31 Neurogen Corporation Capsaicin receptor ligands

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ZIMMERMAN ET AL.: "Structure-Activity Relationships of trans-3,4-Dimethyl-4-(3-hydroxyphenyl)piperidine Antagonists for my- and kappa-Opioid Receptors", J.MED.CHEM., vol. 36, no. 20, 1993, pages 2833 - 2841, XP002314711 *

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7317124B2 (en) 2003-11-13 2008-01-08 Sanofi-Aventis Deutschland Gmbh Ortho-substituted pentafluorosulfanylbenzenes, process for their preparation and their use as valuable synthetic intermediates
US7449594B2 (en) 2003-11-13 2008-11-11 Sanofi-Aventis Deutschland Gmbh Process for preparing 4-pentafluorosulfanylbenzoylguanidines
US7622611B2 (en) 2003-11-13 2009-11-24 Sanofi-Aventis Deutschland Gmbh Pentafluorosulfanylbenzoylguanidines, process for their preparation, use as a medicament or diagnostic aid, and medicament comprising same
US7659429B2 (en) 2003-11-13 2010-02-09 Sanofi-Aventis Deutschland Gmbh Process for preparing 4-pentafluorosulfanylbenzoylguanidines
US7126026B2 (en) 2003-11-13 2006-10-24 Sanofi-Aventis Deutschland Gmbh Process for preparing 4-pentafluorosulfanylbenzoylguanidines
US7932416B2 (en) 2003-11-13 2011-04-26 Sanofi-Aventis Deutschland Gmbh Ortho-substituted pentafluorosulfanylbenzenes, process for their preparation and their use as valuable synthetic intermediates
US7994167B2 (en) * 2005-05-20 2011-08-09 Gruenenthal Gmbh Pentafluorosulphanyl-substituted compound and its use for producing medicaments
WO2008010061A2 (en) * 2006-07-17 2008-01-24 Glenmark Pharmaceuticals S.A. 3-azabicyclo [3.1.0] hexane vanilloid receptor ligands, pharmaceutical compositions containing them, and processes for their preparation
WO2008010061A3 (en) * 2006-07-17 2008-04-17 Glenmark Pharmaceuticals Sa 3-azabicyclo [3.1.0] hexane vanilloid receptor ligands, pharmaceutical compositions containing them, and processes for their preparation
US8044052B2 (en) 2006-10-18 2011-10-25 Pfizer Inc. Biaryl ether urea compounds
US8455520B2 (en) 2007-07-17 2013-06-04 Merck Sharp & Dohme Corp. Soluble epoxide hydrolase inhibitors, compositions containing such compounds and methods of treatment
US8338603B2 (en) 2007-10-24 2012-12-25 Abbvie Inc. TRPV1 antagonists
US8557872B2 (en) 2008-01-28 2013-10-15 Amorepacific Corporation Compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same
EP2259680A4 (en) * 2008-03-04 2012-01-25 Merck Sharp & Dohme Soluble epoxide hydrolase inhibitors, compositions containing such compounds and methods of treatment
EP2259680A1 (en) * 2008-03-04 2010-12-15 Merck Sharp & Dohme Corp. Soluble epoxide hydrolase inhibitors, compositions containing such compounds and methods of treatment
EP2484664A1 (en) * 2008-05-07 2012-08-08 Dainippon Sumitomo Pharma Co., Ltd. Cyclic amine-1-carboxylic acid ester derivative and pharmaceutical composition containing the same
US8367835B2 (en) 2008-05-07 2013-02-05 Dainippon Sumitomo Pharma Co., Ltd. Cyclic amine-1-carboxylic acid ester derivative and pharmaceutical composition containing the same
AU2009245121B2 (en) * 2008-05-07 2013-08-01 Sumitomo Dainippon Pharma Co., Ltd. Cyclic amine-1-carboxylic acid ester derivative and pharmaceutical composition containing the same
US8691855B2 (en) 2008-07-02 2014-04-08 Amorepacific Corporation Compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist and pharmaceutical compositions containing the same
WO2011143365A1 (en) * 2010-05-13 2011-11-17 Amgen Inc. Nitrogen heterocyclic compounds useful as pde10 inhibitors
AU2011253057B2 (en) * 2010-05-13 2014-11-20 Amgen Inc. Nitrogen heterocyclic compounds useful as PDE10 inhibitors
US8957073B2 (en) 2010-05-13 2015-02-17 Amgen Inc. Unsaturated nitrogen heterocyclic compounds useful as PDE10 inhibitors
US9718803B2 (en) 2010-05-13 2017-08-01 Amgen Inc. Unsaturated nitrogen heterocyclic compounds useful as PDE10 inhibitors

Also Published As

Publication number Publication date
EP1682141A1 (en) 2006-07-26
CN1874775A (en) 2006-12-06
GB0325287D0 (en) 2003-12-03
AU2004292382A1 (en) 2005-06-09
JP2007509915A (en) 2007-04-19
US20070135423A1 (en) 2007-06-14

Similar Documents

Publication Publication Date Title
WO2005051390A1 (en) E-fluoro-4-(pyridin-2-yl)-piperidine-1-carboxamide derivatives and related compounds which modulate the function of the vanilloid-1 receptor (vr1) for the treatment of pain
US11981685B2 (en) Bicyclic heterocyclyl derivatives as IRAK4 inhibitors
US6060469A (en) Spiro-piperidine derivatives and their use as tachykinin antagonists
JP5411300B2 (en) Soluble guanylate cyclase activator
US8163756B2 (en) Enzyme modulators and treatments
US5854268A (en) Azetidine, pyrrolidine and piperidine derivatives
CA2479150A1 (en) Heteroaromatic urea derivatives as vr-1 receptor modulators for treating pain
JP2019172676A (en) Inhibitors of lysine specific demethylase-1
JP2008540501A (en) 2,3-substituted fused bicyclic pyrimidine-4 (3H) -one that modulates the function of vanilloid-1 receptor (VR1)
JP2006512323A (en) Amino heterocycles as VR-1 antagonists for the treatment of pain
JP2007511496A (en) Bicyclic pyrimidin-4- (3H) -ones and analogs and derivatives thereof that modulate the function of vanilloid-1 receptor (VR1)
CA2602395A1 (en) 2,3-substituted fused pyrimidin-4(3h)-ones as vr1 antagonists
JP6417338B2 (en) Cis-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer
JP2007523143A (en) Substituted aminoheterobicyclic prodrugs that modulate the function of the vanilloid-1 receptor (VR1)
EP1625119B1 (en) Substituted-1-phthalazinamines as vr-1 antagonists
EP1687293B1 (en) Indazol-3-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1 receptor (vr1)
ITTO960718A1 (en) NEW DERIVATIVES OF PIPERIDINE, PROCEDURE FOR THEIR OBTAINMENT AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
CA2856824A1 (en) Cyclic urea derivatives as androgen receptor antagonists
CA2211189A1 (en) Substituted 1,4-piperazine-heteroaryl derivatives as 5-ht1d receptor agonists
WO2006038041A1 (en) Besylate salts of six-membered amino-heterocycles as vanilloid-1 receptor antagonists for treating pain
AU2003214442B2 (en) Heteroaromatic urea derivatives as VR-1 receptor modulators for treating pain

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200480032236.8

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004292382

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1827/DELNP/2006

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2004769034

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007135423

Country of ref document: US

Ref document number: 10577585

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2004292382

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006537408

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2004769034

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 10577585

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 2004769034

Country of ref document: EP